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ABSTRACT 
Introduction 
Snake bite is one of the most important “Neglected Tropical Diseases” in terms of both 
incidence and severity, and its clinical characteristics. Venom-Induced Consumption 
Coagulopathy (VICC) is the core pathogenic mechanism in haemotoxic snake bites. 
The common derangements seen are prolonged Prothrombin time (PT), prolonged 
Activated Partial Thromboplastin Time (APTT), low/undetectable fibrinogen. VICC is 
characterized by reduction of coagulation factors and the absence of systemic 
microthrombi and end-organ damage. The time course in VICC is rapid- occurring 
within a few hours of envenomation and resolution within 24-48 hours, if treated 
appropriately. 
Objectives 
The primary objective of this study is to identify patients with haemotoxic snake bite 
and to characterize Venom Induced Consumption Coagulopathy (VICC) in these 
patients. The secondary objectives are to study the coagulation profile in patients with 
haemotoxic snake bite and their response to treatment with Anti Snake Venom (ASV) 
and/or blood products. Comparison of sensitivity and specificity of the new test Vellore 
Manually Activated Clotting Time (Vemac Time) against a composite diagnosis of 
VICC. A review of retrospective data spanning a five-year period of the clinical and lab 
parameters of patients with haemotoxic snake who received blood products transfusion 
has also been undertaken. 
 
Methods and Materials 
This is an observational study with a retrospective arm comprising patients who were 
admitted between year 2012-2017 and a prospective arm for patients admitted between 
2017 – 2018 at Christian Medical College, Vellore. 
Results 
Data from 280 patients who had a haemotoxic snake bite were analysed. Among these 
47(16.8%) patients were transfused blood and plasma products. There was a male 
preponderance among patients (70.2%). Isolated haemotoxic features and local reaction 
were seen in 8.5%.  Coexisting neurological and/or renal manifestations were seen in 
more than 90% patients. The average dose of ASV received per patient was 18.9 ±7.75 
vials. Baseline INR more than 1.5 was seen in 87.2% and an elevated APTT ratio was 
seen in 55.3%. All components were transfused: platelet concentrates (30%), FFP 
(66%), cryoprecipitate (32%) and cryosupernatant (11%). Mortality was 10.6% among 
this patient group with transfusions. 
Among the prospective follow up group pure haemotoxicity was seen in 24.3% (n=9) 
patients. Combinations of haemotoxicity with renal and/or neurological manifestations 
were seen in 75.7% (n=28). 
The new test Vellore Manually Activated Clotting Time (Vemac Time) was compared 
against Prothrombin Time and also a composite diagnosis of VICC. The sensitivity of 
the test was found to be 81.82% and specificity was 100% when compared with PT. 
Positive predictive value of the test was 100% when compared with PT. 
When compared to a composite diagnosis of VICC it was found to have positive 
predictive value of 100%.  
Discussion and conclusion 
Snake bite was and still remains a problem that can easily be tackled, if diagnosis and 
treatment is given in a timely manner. The role of a good haemostasis laboratory in 
detecting VICC and management of the patient is emphasized by this study. Antivenom 
is the major treatment for VICC. Treatment focuses on neutralization of venom effects 
with antivenom and waiting for the replenishment of coagulation factors. Antivenom is 
not risk free and adverse reactions can be quite common and potentially severe. Patients 
should be observed in hospital until clotting function has normalised. 
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INTRODUCTION 
Snake bite is a one of the common medical emergencies and also an occupational 
hazard, which is frequently encountered in tropical India. More than 2,000 species of 
snakes are known worldwide. These includes almost 400 poisonous snakes. In India, 
Naja naja commonly known as spectacled cobra, Bungarus caeruleus or the common 
krait, Echis carinatus or the saw-scaled viper and Daboia russelii or the Russell’s viper 
have long been recognised as the most important. Other species which may cause fatal 
envenomation are distributed in certain regions. These includes central Asian cobra 
(Naja oxiana) in the far north-west, monocellate cobra (N. kaouthia) and greater black 
krait (B. niger) in north-east, Wall’s and Sind kraits (B. walli and B. sindanus) in the 
east and west and hump nosed pit-viper (Hypnale hypnale) in the south-west coast and 
Western Ghats. These snakes belong to the four families namely Elapidae, Viperidae, 
Hydrophiidae and Colubridae. The Russell’s viper (Daboia russelii) commonly 
inhabits Southern Asian countries. Russell’s bite is considered as an occupational 
hazard for the farming communities in India. Regardless of the fact that India is neither 
the home for venomous snakes nor there a shortage of anti-snake venom, every year 
there are 50,000 deaths from 2,50,000 incidents of snake bite.  (1).  
There is a paucity of data on the epidemiological profile of snake bite from the Indian 
subcontinent. Commonly rural people are victims of snake bite and use traditional 
healers. These cases go unidentified. Rural people are not well informed about the risks 
of harmful practice and how simple measures can prevent or treat snake bites. They 
adopt harmful practices such as tourniquets, cutting & suction, herbal remedies, 
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quackery etc. These are not only inadequate but also hazardous(2). Only the cases with 
symptoms of severe envenomation reach proper health care services. 
Snake venoms are rich collections of enzymes, proteins, peptides and other components 
that can cause a wide range of physiological, neurological and haemostatic effects on 
their prey. Among these effects, the venom components that affect mammalian 
haemostasis have been most well studied for more than 150 years. They have added to 
the explanation for the extensive mechanisms of the haemostasis process (e.g. platelet 
aggregation and inhibition, mechanism of defibrination, DIC, various coagulopathies, 
etc), elucidation of various clinical disorders (e.g. congenital haemorrhagic disorder, 
various blood factor deficiencies, etc), development of many diagnostics (e.g. Reptilase 
time) and therapeutics (e.g. batroxobin). Therefore, venoms have been regarded as ‘gold 
mines’ for researchers, pharmaceutical companies, clinical analysts and medical 
practitioners (3). 
Qualitatively and quantitatively variation in venom is appreciable in different families 
of snakes (4)(5). In general, snake venoms varies mostly in composition of soluble 
polypeptides, but may also vary in amount of carbohydrates, lipids, metal ions, and 
other organic compounds, including amines and purines (6).  
Almost up to 90% of the dry weight of most venom is comprised of polypeptides of 
three size classes: low molecular weight components (< 1.5 kDa), polypeptide toxins (5 
to 10 kDa), and enzymes (10 to 150 kDa) (3). 
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AIM 
The aim of the study was to characterize the effects of snake bite on the haemostatic 
system, transfusion requirements and effect of transfusion on haemostatic parameters. 
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OBJECTIVES 
The primary objective of our study was: 
1.To identify patients with haemotoxic snake bite and to characterize Venom Induced 
Consumption Coagulopathy (VICC) in these patients. 
 The secondary objectives were: 
1. To study the coagulation profile in patients with haemotoxic snake bite and their     
    response to treatment with Anti Snake Venom (ASV) and/or blood products.  
2.Comparing sensitivity and specificity of the new in house designed test named Vellore   
   Manually Activated Clotting Time (Vemac Time) against a composite diagnosis of    
   VICC. 
3.To retrospectively study for a period of five years the clinical and lab parameters of  
   patients with haemotoxic snake who received blood products transfusion. 
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METHODS AND MATERIALS 
SETTING 
This study was carried out in the Departments of Transfusion Medicine and 
Immunohaematology along with the Departments of Internal Medicine, Accident and 
Emergency and the Medical Intensive Care Unit, at Christian Medical College Hospital, 
Vellore. 
The study was approved by the Institutional Review Board of the Institute IRB no 10467 
dated 05/01/2017. For the part of the study being conducted retrospectively, all patient 
identifying information was completely delinked from the study. 
SAMPLE SIZE CALCULATION 
This was an observational study which was conducted over a period of 15 months. The 
National Snake Bite study from Christian Medical College (CMC), Vellore completed 
in 2016 showed about 170 patients over a period of 2 years. 60-70 patients were 
expected to be recruited in this study. However, only 37 patients with snake bite fulfilled 
the inclusion criteria for this study. 
PARTICIPANTS 
Inclusion Criteria for the prospective study 
1.All consenting patients above 16 years of age presenting to CMC Hospital with 
haemotoxic snake bite within 24 hours. 
2.Patients who have an abnormal Whole Blood clotting time and/or PT with INR  ≥1.2 
with or without bleeding manifestations. 
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Exclusion Criteria for the prospective study 
1.Children (<16 years) 
2.Cases of snake bite with no evidence of envenomation and blood tests remain normal. 
3.Non-consenting patients.  
The patients had the standard investigations and treatment for snake bite as it is 
currently practised in CMC. The results from the various blood tests and the clinical 
course including transfusion requirements of the patient were observed. These were 
analysed to see whether they fulfil the diagnostic criteria described in the literature for 
VICC. 
All categorical clinical profile variables were expressed as frequencies and percentages. 
All continuous variables which were approximately symmetric were presented using 
mean with SD. If not symmetric, median with IQR were presented. 
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REVIEW OF LITERATURE 
GENERAL FACTS ABOUT SNAKES 
WHAT ARE SNAKES? 
Snakes are squamate animals and part of the lizard phylogeny. They are a very diverse 
and specialized group of limbless lizards. Snakes are members of the second most 
speciose group of living reptiles (Reptile Database: http://www.reptiledatabase.org/).  
“Limblessness” has evolved quite commonly among lizards and, including snakes, this 
feature has evolved independently at least 25 times (7). However, no group of limbless 
lizards are as successful as snakes. There are approximately 3,150 species of snake and 
they occur in nearly every habitat and on every continent except Antarctica. 
Snakes are cold blooded animals without ears or tympanic membranes. They react to 
vibrations received through the surface on which they rest and are very sensitive to 
vibrations from movement. Snakes do not have good visual acuity and they do not 
generally associate stationary objects with danger. They have a good sense of smell and 
snakes are well known for the vomeronasal system of odour detection.  Most of the land 
snakes feed on small animals such as mice, rats and frogs. Kraits and Cobras are 
exceptional and mainly eat other snakes.  
EPIDEMIOLOGICAL FEATURES OF SNAKE BITE 
Snake bites are common emergencies encountered in clinical practice. The estimated  
number of persons affected by snake bite is not accurately known, but, it is assumed 
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that more than 2,00,000 persons are annually bitten by snakes in India and about 15,000 
of these turn out to be fatal (8).  
In India, the prevailing climatic conditions and the fact that a major portion of the 
population is rural and agrarian, results in snake bite being a major health problem. 
Snake bite morbidities can be a preventable health hazard in these most affected 
population.  
The death rate from snake bite is estimated to be 5% of bites. However, this figure is 
based on hospital statistics. In practice however, most rural patients are treated by local 
traditional methods and do not reach proper health care facility (9).  
India is a country with more than 60 species of venomous snakes. Spectacled cobra 
(Naja naja), common krait (Bungarus caeruleus), saw-scaled viper (Echis carinatus) 
and Russell’s viper (Daboia russelii) are the well identified venomous snakes. 
However, there are other species in particular regions,  for example,  the hump nosed 
pit-viper (Hypnale hypnale) in the south-west coast and Western Ghats (9) which lead 
to fatal envenomation.  
Almost 26 species belong to the family of true vipers (subfamily Viperinae) and pit 
vipers (Crotalinae). Among them, Russell’s viper (Daboia russelii) envenomation leads 
to the highest morbidity and mortality. Saw scaled viper (Echis carinatus) is commonly 
seen in western and southern India. They are also found in the dry coastal parts of 
northern Sri Lanka. Pit vipers have generally been considered to be less of a problem in 
South Asia. However, these snakes occur in diverse habitat types from wet mangroves 
to high mountains. These are also common in domestic gardens and agricultural areas. 
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Recent literatures from South India have reported high morbidity among plantation 
workers due to bites by the much smaller species, the Malabar pit viper (Trimeresurus 
malabaricus). Hump-nosed pit vipers (Hypnale and H. nepa) are also being identified 
as medically dangerous species in these regions, and can potentially cause renal failure 
and haemostatic abnormalities. Severe fatalities have been documented in India and Sri 
lanka due to H. hypnale envenoming (10). 
 The ‘‘Big 4 Snakes of Medical Importance,’’ namely the Russell’s viper, the saw scaled 
viper, the Indian or spectacled cobra, and the common krait are believed to cause the 
vast majority, of fatalities due to snake bite (1). Venomous snake bite was listed as 
NTD- “Neglected Tropical Disease”, by the WHO in 2009 and it was removed from the 
list in 2013. It was again recognised by the World Health Organization (WHO) in the 
category A of the Neglected Tropical Diseases on June 9th, 2017 (11). It indicates that 
snake bite is prevalent in tropical and subtropical conditions in 149 countries affecting 
more than a billion people, costing developing economies billions of dollars of loss 
every year. Worldwide, approximately 4,21,000 envenoming and 20,000 deaths occur 
annually from snake bites. Figures are reported to be as high as 1,841,000 bites with 
envenomation, leading to almost 94,000 deaths (12). Not all snake bites lead to 
envenomation. In general one third of snake bites causes envenomation(10).  
SOCIO DEMOGRAPHIC FACTORS 
The increase in population numbers and population spread leads to encroachment by 
people into reptile habitats which increases the likelihood of contact with reptiles. 
Inadequate infrastructure in villages, including poor lighting, open sewerage systems, 
roads, lack of in-house water supply may all co-contribute to bites especially occurring 
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at night. Improper sanitation contributes to increase in rodent population and therefore 
snake presence. Poor transport facilities in rural areas leads to significant and at times, 
fatal delays in transportation of patients to medical care facilities (13).  
SOCIO-CULTURAL 
Most people who live in villages lacks protective foot wear, and sleep on the ground.  
Livestock are also present in close proximity to houses which draw rats to these places 
and therefore their predators too. Lack of toilet facilities leading to open defecation, 
quite often after sunset are all important socio-cultural contributory factors (13).  
MEDICAL 
Medical awareness among victims and their families, of the immediate measures to be 
followed when bitten by a snake is lacking. Precious time is lost when alternate or 
traditional forms of treatment are sought. Inadequate first aid measures leads to systemic 
envenomation and added complications (13).  
LEGISLATIVE / GOVERNMENTAL 
The process of manufacture of Anti-Snake Venom (ASV) and also its standardization 
lacks centralised quality control. The venom used for the manufacture of ASV for the 
entire country is from one or two sources and is limited to a small geographical area. 
Research has shown regional variation in venom constituents and chemical properties, 
as well as intra-species variation. Regional/zonal venom centres with the facilities to 
manufacture ASV for a particular region or zone are therefore important to ensure 
appropriate ASV availability (13).  
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TAXONOMY, IDENTIFICATION AND DISTRIBUTION OF SNAKES 
There are about 2500 to 3000 species of snakes of which about 500 belong to the five 
families of Venomous snakes, Atractaspididae, Elapidae, Hydrophidae, Colubridae 
[some species] and Viperidae. In India 236 different species of snakes are seen, of which 
50 species are identified as being poisonous. Among the non-venomous snakes only the 
giant constrictors are potentially dangerous to man – these include the South African 
and Asian pythons, and the South American anaconda . 
Poisonous snakes prevalent in India belong to four families. 
They are 
1. Elapidae – includes cobras & krait 
2. Viperidae (true vipers) – includes Russell’s viper & saw scaled viper. 
3. Colubridae ( pit vipers) – includes green pit viper. 
4. Hydrophidae (or) sea snakes. 
  
Elapidae, Viperidae and Colubridae are three families of venomous snakes in South-
East Asia: 
Elapidae: This family of snakes have relatively short fixed front fangs. It includes 
cobras, king cobra, kraits, coral snakes, Australasian snakes and sea snakes. They are 
relatively long, thin and uniformly-coloured snakes. They possess large smooth 
symmetrical scales on the dorsum of the head.  They lack loreal scale between their pre-
ocular and nasal scales. Two species of cobras are found in India, common cobra (Naja 
naja) and king cobra (Ophiophagus hannah). The head of the cobra is indistinct from 
the neck and the ribs in this area are movable and can expand to form the hood. This 
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hood on its dorsal aspect has a marking which resembles a spectacle showing a 
connected pair of rings.  King Cobras are found in dense forests and can be up to a 
length of 18 feet. They are usually black in colour. 
Two species of Kraits are commonly found in India. The Common Krait and Banded 
krait - Common krait is steel blue or black with white bands on the back. Banded krait 
is larger and is jet black in colour with yellow bands. 
 Viperidae: In contrast to above family these snakes have relatively long fangs. These 
fangs are normally folded flat against their upper jaw. When they bite, it becomes 
erected. They are further divided into two subfamilies, true vipers (Viperinae) and pit-
vipers (Crotalinae).  
Russell’s viper is a larger snake measuring 6 feet and makes a loud hissing sound by 
expelling air through its large nostrils. It can appear sluggish and stout. It is brown or 
yellowish with dark round spots on the dorsum with white and black edges (14).  
Saw scaled viper a small snake (30cm long) with brown or grayish dorsum showing a 
zig zag pattern. It has a distinct cross or lance shaped mark on the head. The ventral 
scales are rough. They can produce a grating sound by rubbing their coils together.  
The other sub family Crotalinae possess a well formed infra-red heat-sensing organ, 
the loreal pit organ, to detect their warm-blooded prey. This is situated between their 
nostril and the eye.  
Colubridae: The third group among the venomous snakes include colubrids. They make 
up the largest group of snakes and almost include 75 percent of all the world's snake 
species. Most of the these possess wide scales on their bellies and, usually, nine large 
scales on the tops of their heads. They also have glands behind each eye. These glands 
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release a mixture of chemicals. Their venom usually takes minutes to act unlike the 
cobras and vipers, whose fast-acting venom can kill their prey in moments. 
 
Non-venomous snakes  
Several species of non-venomous snakes are responsible for bites.  These commonly 
are found in urban and rural gardens. Humans are liable to their bite when approached 
too closely. Notably  Lycodon and Dryocalamus mimics krait, resulting in unnecessary 
medical treatment (15).  
Identification of venomous snakes 
There is no simple general rule for identifying a venomous snake. Some harmless 
snakes have evolved to look almost identical to venomous ones. Various species of 
Lycodon, Dryocalamus and Cercaspis mimic the appearance of the kraits B. candidus, 
B. caeruleus and B. ceylonicus. The tail raising display and colouring of Cylindropis 
ruffus, may mimic coral snakes (Calliophis species). Most of the venomous snakes can 
be recognized by their size, shape, colour, pattern of markings, characteristic behaviours 
and sounds made when they feel threatened. When a cobra is threatened they spread a 
hood, hiss and make continuous strikes. There can be vast differences in the colour 
pattern between the same species of snakes. However distinct identification can still be 
made, like the possession of longitudinal rows of large, dark-rimmed, pale-centred spots 
of the Russell’s vipers, or the alternating black and yellow circumferential bands of the 
banded krait. Snakes can even be distinguished by other characteristics like blowing 
hiss of the Russell’s viper or a grating rasp of the saw-scaled viper (16). 
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THE VENOM APPARATUS:  
The evolution of altered teeth capable of injecting venom evolved over millions years 
ago (16). Among the venomous snakes Elapidae and Viperidae, venom glands are 
situated behind the eye, surrounded by compressor muscles. The duct from these glands 
opens at the base of the fang. The venom flows through a groove to the tip of the 
fang(16). In Elapidae fangs are seated in the front of the mouth. In Viperidae fangs are 
seated on a rotatable maxilla which can be folded flat against the roof of the mouth. In 
Colubridae venom secreted by Duvernoy’s (supralabial) glands which are positioned at 
the posterior end of the maxilla (17). Fangs allow the snake to inject venom deep into 
the tissues of its prey. Venom is generally injected subcutaneously or intramuscularly. 
Spitting cobras ejects the venom from the tips of their fangs in a skilful spray aimed 
towards the eyes of an intruder (16).  
 
SNAKE VENOM 
90% of the dry weight of snake venom is composed of more than a hundred varieties of 
proteins comprising of enzymes, non-enzymatic polypeptide toxins, and several other 
non-toxic proteins. The enzymes include digestive hydrolases, hyaluronidase 
(spreading factor), yellow L-amino acid oxidases, phospholipases A2, and peptidases 
(16).  
Snake venom metalloproteases (SVMPs) may cause damage to the basement membrane 
resulting in severe endothelial damage causing spontaneous systemic bleed. 
Procoagulant enzymes includes activators of factors V, X, prothrombin and other 
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clotting factors, causing Disseminated Intravascular coagulation (DIC) or incoagulable 
blood.  
Phospholipases A2 can damage intracellular organelles and may produce wide spread 
toxicity which may include presynaptic neurotoxicity, cardiotoxicity, myotoxicity; 
tissue damage resulting in necrosis, hypotension, haemolysis, anti-coagulation, 
haemorrhage, plasma leakage (oedema formation) and release of histamine and other 
autacoids. Polypeptide postsynaptic (α) neurotoxins bind to acetylcholine receptors at 
the motor endplate. Presynaptic (β) neurotoxins are phospholipases that permanently 
damage nerve endings.  
The chemical content and antigenicity of snake venoms varies strikingly between and 
within species, as these snakes mature, depending on season, between sexes, and in their 
geographical distribution. Thus, it is very important to note that envenoming by a 
particular species of snake in certain part of its geographical range may not be showing 
repose to an antivenom prepared against venom from the same species in some else 
location.  
 PATHOPHYSIOLOGY OF HUMAN ENVENOMING 
Snake bite causes swelling and bruising locally as a result of the venom. This causes 
increased vascular permeability. Tissue necrosis can be seen because of thrombosis, 
tight tourniquets applied as first-aid, fascial compartments with swollen muscles (16). 
Hypovolaemia due to leakage of plasma may lead to severe hypotension. Other released 
oligopeptides like ACE inhibitors and bradykinin-potentiating peptides (BPPs) which 
are vasodilating autacoids can cause early transient hypotension. Injection of 
procoagulant enzymes lead to defibrinogenation, or a consumptive coagulopathy. 
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Platelet activation/inhibition and sequestration leads to profound thrombocytopenia. 
Certain metalloproteinase example zinc metalloproteases (haemorrhagins) are reasons 
for spontaneous systemic bleeding.  
Complement activation can directly affect platelets, blood coagulation and another 
humoral activator. Venoms from elapid and some colubroid activate the alternative 
pathway, while the viperid venoms activates the classical complement pathway. 
Neurotoxic polypeptides and PLA2s injection manifests as paralysis by blocking 
transmission at neuromuscular junctions. Descending paralysis affects bulbar and 
respiratory muscles leading to upper respiratory airway obstruction, aspiration, or even 
respiratory paralysis. Anticholinesterase drugs (e.g. neostigmine) can be used for the 
treatment of these manifestations. Generalized rhabdomyolysis, myoglobinaemia, 
myoglobinuria leading to acute kidney injury can be seen in PLA2 myotoxins and 
metalloproteases in the venoms of sea snakes, terrestrial Australasian elapids and some 
kraits. 
 Russell’s vipers quite commonly cause acute kidney injury. The histopathological 
features seen include acute tubular necrosis, proliferative glomerulonephritis, bilateral 
renal cortical necrosis, acute interstitial nephritis, toxic mesangiolysis with platelet 
agglutination, fibrin deposition and ischaemic changes. Kidney injury may be direct 
result of hypotension, hypovolaemia, direct nephrotoxicity or secondary to 
haemoglobinuria, myoglobinuria, and hyperkalaemia.  
DIC may result in inappropriate deposition of fibrin that has been stimulated by 
metalloproteases on the vascular endothelium, producing microangiopathic haemolysis 
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and thrombotic microangiopathy (TMA). These manifestations resemble haemolytic 
uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), 
but interestingly A Disintegrin And Metalloproteinase with a ThromboSpondin Type 1 
Motif, Member13 (ADAMTS13) levels are never low. 
ENZYMATIC EFFECTS OF SNAKE VENOM 
The most important and common enzymes in snake venoms are: 
a) Phospholipase A2s (PLA2s),  
b) Serine proteinases, metalloproteinases, 
c) Acetylcholinesterases (AChEs),  
d) L-amino acid oxidases,  
e) Nucleotidases (5-nucleotidases, ATPases, phosphodiesterases and DNases)  
f) Hyaluronidases. 
There are several other non-enzymatic polypeptides which include cysteine-rich 
secretory proteins (CRiSPs), nerve growth factors, PLA2-based neurotoxins, non-PLA2 
myotoxins, C-type lectins, disintegrins, bradykinin potentiators, and tripeptide 
inhibitors. 
Acetylcholinesterase (AChE): 
The exsistence of AChE in cobra venom was first demonstrated in 1938. Large amounts 
of AChE can be quantitated from the venom of snakes, specifically in species belonging 
to the family Elapidae, with Dendroaspis species as an exception. In contrast, AChE is 
not found in venoms of snakes belonging to the Viperidae and Crotalidae families. 
Incidentally, snake venom AChEs are also more active than Torpedo and mammalian 
AChEs in hydrolyzing AChVenom affects a wide range of physiological functions in 
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the envenomated organism, and each individual venom component may have a 
distinctive function.  
Phospholipases A2 (PLA2): 
Almost all snake venoms contain phospholipases A2 (PLA2), which acts through cell-
destruction leading to oedema, lipolysis, or myolysis (18).  
Nucleotidases: 
These includes 5-nucleotidases, ATPases, phosphodiesterases and DNases. 
Phosphodiesterases are a group of enzymes, which causes hydrolysis of phosphodiester 
bonds. This catalysis is mostly seen as a breakdown of nucleic acids, including DNA 
and both types of ribonucleic acids (RNAs), the ribosomal RNA and the transfer RNA. 
These enzymes can also affect many other nucleotides and nucleic acids as well (19). 
Although the overall effect has not been fully evaluated, it would appear that the 
depletion of such nucleotides results in hypotension and/or shock. 5’- nucleotidases 
attack nucleic acid at the 5’ carbon position, degrading the sugar moieties of both DNA 
and RNA. The overall effect of 5’- nucleotidases is to release nucleosides from nucleic 
acids. One group that affects nucleic acids is the alkaline phosphomonoesterases, which 
hydrolyze phosphomonoesterases at pH above neutral. The biological effect of the 
alkaline phosphomonoesterases is not entirely clear, but these three groups of enzymes 
attack nucleotides in different manners, and all three are present in viperid venoms.  
Hyaluronidases: 
Hyaluronidases are also commonly called “spreading factors” because of their capacity 
to degrade hyaluronic acid. Hyaluronic acid is a ubiquitous component of the 
extracellular matrix of tissues, and is in part responsible for cementing cells together 
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(20). Hyaluronidases have been found in the venom of all elapidae and viperidae venom 
(21). After degradation of hyaluronic acid by hyaluronidase, the extracellular matrix 
breaks down allowing the remaining venom components to spread through the tissue, 
since their movement is not restricted. This can lead to both localized necrosis, as 
nearby cells are destroyed by other venom components. Systemic effects also occur as 
other venom components spread into the blood stream through blood vessels made 
permeable or leaky by the hyaluronidase.  
L-amino acid oxidases: 
L-Amino acid oxidases (LAAOs) catalyse the oxidation of L-amino acids via a two-
step deamination process. As a result of the deamination process there is a general 
deterioration of amino acids that leads in cell death (22).  
Proteases: 
Proteolytic enzymes are those enzymes that lead to the degradation of structural proteins 
into component peptides or amino acids. They have great digestive capability and can 
hydrolyze proteins in their native (non-denatured) state through cleavage of peptide and 
ester bonds. Metalloproteinases (because of their reliance on metal ion co-factors) and 
serine proteases (because of their similarity to blood factors) are two of the major 
subgroups among these enzymes in venom. Metalloproteinases cause haemorrhage and 
necrosis, but may also have a function in the digestion of prey.  
Serine proteases: 
Serine proteases disrupt hemostasis and may do so through multiple mechanisms. 
Serine proteases are generally placed into three categories, depending on their mode of 
action (23). The thrombin-like serine proteases cleave fibrinogen at the same position 
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as thrombin. This leads to a rapid depletion of fibrinogen. The resulting fibrin, is not 
coagulable due to a lack of fibrin stabilizing factor leading to an overall anti-coagulation 
effect (24) (25) (26). Kallikrein-like serine proteases release bradykinin from high 
molecular weight kininogen and causes degradation of angiotensin. This leads to a drop 
in blood pressure (27). Arginine esterases have enzymatic activities against peptide and 
ester substrates, but their biological effects are not fully understood (28).    
CRiSPs have varied functions in different species It ranges from disruption of potassium 
or calcium currents in the  neurons to the induction of hypothermia (29). The functions 
of many similar CRiSPs in other species have not been demonstrated yet. Nerve growth 
factors stimulate the growth of nerve cells and are found in venoms of both viperidae 
and elapidae. PLA2-based presynaptic neurotoxins act by blocking release of 
acetylcholine from axon terminals leading to a flaccid paralysis. They have strong 
neurotoxic functions and include the Mojave toxin found in certain rattlesnake species. 
The non-PLA2-based myotoxins, disrupt voltage-sensitive sodium channels, causing 
immobilization of the prey and myonecrosis. C-type lectins and disintegrins alter the 
coagulation cascade, but in different manners. C-type lectins bind to platelets. This can 
cause initial clotting or it can cause platelets to be removed from forming clots, 
depending on the specific form of the lectin (30).  
Disintegrins disrupts platelet aggregation, and they are often found grouped with a 
metalloproteinase. Some disintegrins stop the  initial aggregation, while others work by 
disrupting  the already formed aggregates (31). Bradykinin potentiating peptides (BPPs) 
act by being an effective inhibitor of angiotensin converting enzyme (ACE). ACE 
converts angiotensin I into angiotensin II. Angiotensin II causes vasoconstriction. BPPs 
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block ACE activity and also may have a direct effect on angiotensin II.  Both these 
actions lead to a reduction in vasoconstriction thereby allowing bradykinin to cause 
vasodilation and hypotension. Snake venoms also contain factors that help stabilize 
these other components. These include tripeptide inhibitors and citrate (32). The action 
of these seem to be to inhibit the enzyme interactions in the venom. This is to prevent 
the biological functions from occurring till the venom has been injected into potential 
prey and dispersed.  
Many other venom components have been characterized including many other toxins, 
blood clot disruption factors, and some enzymes.  
CLINICAL FEATURES OF SNAKE BITE 
Dry bites: Only about 50% of venomous snakebites lead to envenomation. 
Local features of Envenomation–  
Fang marks: One must not exclude envenomation because of the lack of fang marks. 
Certain bites can be difficult to note, even just after the bite. 
Pain: Pain develops immediately generally spread upwards. The lymph nodes draining 
the bitten areas may become painful.  
 Local swelling: Intense local reaction is seen with viper bites than any other snakes. 
Swelling can be visualized within 15 minutes and may remain up to 3 weeks. It spreads 
rapidly and often involve the whole limb. Lymph node swelling may also develop. 
Necrosis develops in the limb with tight fascial compartments. 
Local necrosis: Local necrosis is seen commonly with viper bites. 
Secondary infection: This may happen secondary to bacterial colonies in snakes. 
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General features: General symptoms include flushing, breathlessness, palpitations, 
and dizziness. Apart from these the other early symptoms in elapid bites include 
vomiting, heaviness of eyelids, blurring of vision, hypersalivation, congested 
conjunctivae. Abdominal discomfort is often followed by diarrhoea. Nausea and 
vomiting may be a common feature of all severe envenomation (33).  
Systemic features- 
Clotting defects and haemolysis: These are common features seen in envenoming by 
Viperidae. Continuous bleeding from the bite site, injection sites, and partially healed 
wounds hints that the blood is haemostatically unstable. Spontaneous systemic 
haemorrhage may occur and sometimes intravascular haemolysis can be observed.  
Neurotoxicity: Elapid and sea snake venoms cause significant neurotoxicity. Ptosis and 
external ophthalmoplegia appear develops within minutes of the bite. Sometimes there 
can be a delayed onset of symptoms. Later on, laryngeal muscles may become 
paralysed. All these predisposes to respiratory failure. These symptoms are completely 
reversible on treatment to anti-venom or spontaneously reverts in a week time.  
 Myotoxicity: Sea snake venom causes myopathy and rhabdomyolysis. Trismus is also 
commonly seen. Rhabdomyolysis leading to myoglobinuria appears within hours of the 
bite. 
Cardiotoxicity: Viper and elapid venom can cause severe myocardial damage. 
Nephrotoxicity: Acute tubular necrosis, bilateral cortical necrosis and renal failure is 
secondary to ischaemia, nephrotoxic effect of venom, pigment nephropathy associated 
with rhabdomyolysis or intravascular haemolysis in Viper bites (especially Russell's 
viper).  
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Shock: Shock precipitates because of hypovolemia, myocardial compromise, and 
adrenal or pituitary haemorrhage (33). 
FEATURES OF ENVENOMATION BY DIFFERENT FAMILIES OF SNAKES 
Elapidae (krait / cobra) - Dominant manifestation is neurotoxicity. Local blisters and 
necrosis can occur. Australian Elapides can also cause bleeding manifestations. 
Viperidae (Russell’s viper / Saw scaled viper) - Local swelling, cellulitis, regional 
lymphadenitis and bleeding manifestations. 
Hydrophiidae (sea snake) – Rhabdomyolysis  
Colubridae - Bleeding manifestations and renal failure. 
 
DIAGNOSTIC APPLICATIONS OF SNAKE VENOM 
There are several diagnostic application of snake venoms in the haemostasis laboratory. 
It can be utilized in assay for every coagulation factor or factor involved in 
fibrinolysis.(34). 
Snake venom as thrombin-like enzyme 
Snake venom thrombin-like enzyme (SVTLE) includes several serine proteases. 
Several snake species have been known to possess more than 100 thrombin-like 
enzymes which resemble thrombin factor both functionally and structurally (35). The 
term thrombin-like enzyme refers their capacity to trigger the clotting of fibrinogen. 
The sources of thrombin-like enzymes are from the pit viper family, like the 
Agkistrodon, Crotalus, Lachesis and Trimeresurus from the true viper family. Snake 
venom thrombin-like enzymes can be obtained from Bitis gabonica, Cerastes vipera, 
Dispholidus typus and from the Colubridae family (36). Thrombin cleaves fibrinogen 
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into fibrinopeptide alpha (FPA) and fibrinopeptide beta (FPB). Some of these enzymes 
cleave fibrinogen and are known as Snake venom thrombin-like enzyme.  
Snake venom thrombin-like enzymes are used to determine the presence of fibrin 
degradation product, dysfibrinogenaemias and defects in fibrin polymerisation. This 
test is commonly known as the Reptilase time. This test sometimes can be used as an 
alternative to more commonly used thrombin time. Dysfibrinogenaemia will manifest a 
prolonged reptilase time. If the prolongation in reptilase time is lesser compared to that 
of the thrombin time, it indicates the presence of fibrin degradation products (34). 
Snake venom as prothrombin activators 
Many snake venoms are composed of prothrombin activators and are utilized in 
prothrombin assays, to demonstrate dysprothrombinaemias (37).  
Meizothrombin an intermediate product in the clotting of whole blood is produced as a 
conversion of prothrombin to thrombin in systems which are composed of purified 
factor Xa and factor Va that are quantitatively assembled on an anionic phospholipid 
surface(38). Ecarin from saw-scaled viper (Echis carinatus) venom, textarin from the 
Australian brown snake (Pseudonaja textilis) and the enzyme from the taipan 
(Oscutarin) are  commercially available prothrombin activators (39). Snake venom 
prothrombin activators are categorized into four groups based on the structural and 
functional properties in prothrombin activation (40).  
Group I activators  
These activators are not affected by the non-enzymatic cofactors of the prothrombinase 
complex (CaCl2, factor Va and phospholipid). They can competently transform 
prothrombin into meizothrombin.   
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Group II activators 
They require only calcium. 
Group III activators 
They require calcium and phospholipids. They do not depend on factor V at all.  
Group IV  
They require all the cofactors including Ca2+, factor V and phospholipid.  
The primary product from digesting prothrombin with ecarin is meizothrombin, which 
was very rapidly converted to thrombin. The in vivo activation of prothrombin to 
thrombin occurs when a complex involving a serine proteinase factor Xa and factor V 
which is a cofactor (prothrombinase complex) assemble on a negatively charged 
phospholipid membrane.  
The factor Xa-like snake venom proteases are seen in trocarin, oscutarin and ecarin. 
These venom proteins convert prothrombin to thrombin (40). 
 Snake venom proteins as factor V activators: 
Thrombin activates factor V (FV) into FVa and a thousand-fold increase in catalysing 
power of factor Xa. Under normal physiological state the cofactor activity of factor Va 
in prothrombin activation is dampened by activated protein C. The venoms of Daboia 
russelli and Daboia lebetina contain a serine protease that accurately activates Factor 
V. The enzyme can be used for routine assay of FV due to the ability of the venom 
protein to activate factor V.  
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Snake venom as factors VII and X activators 
A protease that activates factor VII has been isolated from the venom of Oxyuranus 
scutellatus (taipan snake). It cleaves single-chain human factor VII to yield a two-chain 
molecule which is not distinguishable from the true factor VIIa.  
Factor X activators have been obtained from the venom of many snake species 
belonging to the genus Viperidae and Crotalidae.  It is also sourced from a few Elapid 
species. The best-known activator of factor X is the Russell’s viper venom -X from 
Russell's viper. The Russell’s viper venom -X is a metallo protease and share homology 
with C-type lectins which regulates Ca2+ -dependent activation of factor X. Russell’s 
viper venom (RVV) that activates factor X is commercially available. 
It is also engaged in a number of assays, like measurement of factor X, for 
differentiating between factor VII and factor X and in lupus anticoagulant (LA) assay.  
The clotting time of plasma using Russell’s viper venom -X is known as the Stypven 
time and a normal Stypven time used together with a prothrombin time (PT) suggests 
factor VII deficiency. A prolonged Stypven time indicates factor X deficiency (40).  
Snake venom proteins in the assay of Protein C 
 Protein C is an important component of the natural anticoagulant pathway. The 
inability of activated Protein C to cleave factors Va or VIIIa is known as activated 
protein C resistance. Protac, is derived from Southern copperhead (Agkistrodon 
contortix) snake venom (ACV). It is used in a Chromogenic assay to identify a defect 
affecting the protein C/protein S (PC/PS) anticoagulant system and is based on the 
activation of endogenous plasma protein C  
Snake venom proteins used in the assay of Lupus anticoagulant (LA) 
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Russell Viper Venom directly activates FX, bypassing FVII of the extrinsic pathway 
and the contact and anti haemophilic factors of the intrinsic pathways. Therefore, 
DRVVT tests are more specific for LA than APTT as they are not affected by contact 
factor abnormalities nor by FVIII deficiency or antibodies to FVIII. Heparin levels up 
to 1u/ml have no effect due to the presence of a neutralizing agent in both the screen 
and confirm reagents (40).  
Snake venom proteins used in the assay of defects in platelet plug formation 
Many snake venom proteins have been identified which affect the platelet plug 
formation. These exert their action by either interacting with platelet integrins, 
membrane glycoprotein Ib (GPIb), or plasma von Willebrand factor. 
a. Von Willebrand factor (vWF). 
 Platelet aggregating protein (Botrocetin)is found in the venoms of Bothrops jararaca.  
This protein relies on the presence of von Willebrand factor (vWF) for its effect on 
platelets. This property has been utilized in vWF assay.   
Alboaggregin-B, a venom protein from white-lipped pit viper “Trimeresurus 
albolabris” venom is used to measure vWF receptors on the GPIb molecule (40).  
 
b. Platelet Glycoprotein (GPIb)  
GPIb-binding proteins from snake venoms origin can be divided into two groups: GPIb-
agonists and GPIb-antagonists.    
Alboaggregins from the white lipped viper venom can be of various types A, B and C. 
Alboaggregin B was the first GPIb agonist to be purified. They hinder platelet 
agglutination by VWF. They bind to GPIb and cause platelet aggregation.  
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Another protein Alboaggregin A binds GPIb and GPVI and mediates platelet 
aggregation.  
A few other venom proteins also affect GPIb. Agglucetin from A. acutus agglutinates 
platelets via GPIb receptors. They activate surface expression of GPIIb/IIIa of intact 
platelets.  
COAGULOPATHY IN SNAKE ENVENOMATION 
 
The coagulopathy produced in people by snake envenomation is related to the multiple 
venom components affecting haemostasis. The potential clinical problems are: 
 Decreased blood coagulability and an increased bleeding tendency 
 Frank haemorrhage due to blood vessel wall damage 
 Secondary effects of increased haemorrhage like hypovolaemic shock and 
secondary organ damage, such as intracranial and anterior pituitary haemorrhage 
or kidney injury 
 Direct pathologic thrombosis and its sequelae (e.g. pulmonary 
thromboembolism) (41) 
Haemorrhage in snake envenomations occurs due to abnormal coagulation factors, 
capillary endothelium or platelet function (42). Viperid and Crotalid venoms are rich in 
metalloproteinases (haemorrhagins), which cause local haemorrhage following 
intradermal or subcutaneous venom injection. This is attributed to their ability to 
degrade extra-cellular matrix proteins, particularly type IV collagen, which is a major 
component of the basement membrane. Endothelial cell adhesion to the basement 
membrane is disrupted, which compromises the blood vessel wall integrity. Patients 
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envenomed by Viperid or Crotalid snakes sometimes suffer from systemic haemorrhage 
with absence of evidence of coagulation abnormalities. This finding suggests that 
systemic haemorrhage can be due to a venom-induced platelet disorder. Venom 
metalloproteinases impedes platelet interaction with collagen and vWF by various 
mechanisms by targeting platelet receptors or their ligands. Zinc-dependent 
metalloproteinases from viperid snake venoms were documented to be mainly 
responsible for the haemorrhagic syndrome in snake bite envenomations. Many snake 
venoms contain procoagulant toxins that activate the coagulation cascade (50). The 
venom of the Brown snakes (Pseudonaja spp.) and taipans (Oxyuranus spp.) were 
shown to contain group C prothrombin activators. They were similar to the mammalian 
prothrombinase (Xa:Va) complex and activated coagulation, which leads to 
development of a consumptive coagulopathy. This is now referred to as a venom-
induced consumptive coagulopathy (VICC) and is characterized by prolonged clotting 
times, low fibrinogen, FV and FVIII depletion and high FDP concentrations. The 
consequence of VICC has often been thought to be DIC, due to the elevated D-dimer, 
prolonged PT, and hypofibrinogenaemia. However, a recent publication stated that 
other important features of DIC like the evidence of systemic micro thrombi and end-
organ damage are absent in VICC. A clinical syndrome consistent with thrombotic 
microangiopathy has been reported in a few patients with VICC. It was suggested that 
the presence of thrombotic microangiopathy and VICC in these patients is the likely 
reason for mistakenly diagnosing DIC in such cases (43). 
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VENOM INDUCED CONSUMPTION COAGULOPATHY: PATHOGENESIS 
The basic pathogenic mechanism involved in haemotoxic snake bites is called Venom 
Induced Consumption Coagulopathy (VICC). Snake venom has toxins that induce 
factor activation and the coagulation cascade in vivo leading to coagulopathy. These 
toxins are capable of producing coagulation in vitro as well and are called procoagulant 
toxins. The severity of VICC is directly related to the number and quantity of these 
activators in each snake venom which determines its potency. 
Following envenomation by a haemotoxic snake bite, the common derangements seen 
are prolonged Prothrombin time (PT), prolonged Activated Partial Thromboplastin 
Time (APTT), low or undetectable fibrinogen and low or undetectable factor V, VIII 
and X levels. The different haemotoxic venom toxins and their effects are described 
below. 
Prothrombin activators: 
Prothrombin activators are from the serine protease family have been classified based 
on structure, function and cofactors required. They are divided into groups A to D.  
Prothrombin activator Action 
Group A (Echis spp) Directly activate Thrombin to Meizothrombin 
Group B (Echis, Russell’s viper) Directly activate Thrombin to Meizothrombin 
Group C (Elapids) Resemble Factor Xa-Va complex and activate Prothrombin 
Group D (Elapids) Resembles Factor Xa 
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Factor X and V activators: 
The characteristic toxins in Russell’s viper venom are individual factor activators. 
Activation of Factor X gives rise to Prothombinase complex and leads on to positive 
and negative feedback loops resulting in the utilisation and consumption of Factors V 
and VIII. 
Thrombin-like enzymes (Fibrinogenases): 
These factors are responsible for direct activation and consumption of fibrinogen. They 
belong to the family of Zinc metalloproteinases. These enzymes lyse either the alpha 
chain or beta chain of Fibrinogen resulting in its depletion. The fibrin produced is lysed 
by the body’s own mechanisms. 
Haemorrhagins: 
They belong to the Group A and B prothrombin activators and possess additional 
functions. The Echis spp venom contain these are proteolytic enzymes and cause 
damage to the integrity of blood vessel walls. The basement membrane is disrupted and 
suffers shear stress injury which leads to increased risk of severe and spontaneous 
bleeding.  
Fibrinogen is the most consistently consumed factor and is the final common pathway 
in VICC induced by haemotoxic snake envenomation.  
The risk of bleeding in VICC is due to the following causes- 
1) Coagulation Cascade Activation 
2) Damage to basal membrane and blood vessel wall integrity  
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3) Effects on Platelet count and function 
4) Local toxic and enzymatic effects 
VICC is commonly associated with local bleeding manifestations from the bite site/ as 
well as the site of cannula insertion. However, distal and systemic bleeding such as gum 
bleeding, gastrointestinal or genitourinary bleeding and intracerebral haemorrhage are 
also seen. Echis spp have haemorrhagins in their toxins and therefore cause the more 
serious bleeding manifestations (44). 
As VICC often coexists with thrombocytopenia, it led to the popular belief that VICC 
is a form of Disseminated Intravascular Coagulation (DIC). However, VICC is now 
considered to be a form of Consumptive Coagulopathy which occurs due to the 
consumption of coagulation factors due to activation by venom toxins and depletion of 
fibrinogen rather than a form of DIC which occurs as a result of the activation of 
fibrinolytic system.  
Isbister et al, reported in 2010 that there are significant differences between VICC and 
DIC. VICC specifically does not have systemic microthrombi or end-organ damage due 
to these thrombi. DIC is specifically mediated via the tissue factor/ VIIa pathway while 
initiation of VICC can occur at any point in the coagulation cascade upstream from 
thrombin. The time course in VICC is also very rapid in comparison to DIC and occurs 
within a few hours of envenomation and it also resolves without major sequelae within 
24-48 hours (42).  
The action of thrombin-like enzymes alone, as in Echis spp envenomation results in a 
mild hypofibrinogenemia, also called partial VICC. When the toxins contain other 
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factor activators which lead to the interactions of several other factors such as Factor X 
and V activators, there is resultant complete VICC and severe bleeding. Severe VICC 
is characterized by undetectable Fibrinogen levels, unrecordable Prothombin time and 
elevated d-Dimer levels.  
DIC, on the other hand is characterized by activation of the coagulation cascade via the 
Tissue factor and/or factor VIIa pathway. This leads to an imbalance between the 
procoagulant and anticoagulant pathways resulting in unchecked activation of 
downstream coagulation cascade. There is also a depressed fibrinolytic system leading 
to impaired fibrin removal. 
DIC has a much higher level of morbidity and mortality as compared to VICC. 
Intracranial haemorrhage is often the cause of mortality due to VICC in hospitals. 
However, the prognosis overall is much more favourable with VICC as compared to 
DIC.  
THROMBOCYTOPENIA AND THROMBOTIC MICROANGIOPATHY WITH 
HAEMOTOXIC BITES: 
In about 40-60% of patients with haemotoxic envenomation, VICC coexists with 
thrombocytopenia. There are numerous mechanisms that cause low platelets in snake 
envenomation. The proposed mechanisms include Direct venom-induced platelet 
destruction, immune-mediated platelet toxicity, microangiopathy and suppressed 
platelet production. (46) 
Isbister has shown in his descriptive clinical studies of Russell’s viper in Sri Lanka, that 
a proportion of patients have thrombocytopenia with acute kidney injury.  He has 
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referred to this subset as having VICC with associated thrombotic microangiopathy 
(TMA) (47). As stated therefore, not every case of VICC results in TMA. These are two 
distinct entities, but which are closely interrelated.   
The final consensus on whether VICC is purely a consumptive coagulopathy or DIC 
and the relationship between VICC and microangiopathy is at present unclear. 
However, it is strongly stated in literature that VICC is a distinct entity. At CMC 
Hospital, we have observed that a spectrum of pure VICC, VICC with 
thrombocytopenia and VICC with thrombocytopenia and laboratory evidence of 
thrombotic microangiopathy all exists. We hope that the present study will provide 
further evidence towards clarification of this spectrum in different clinical syndromes 
of viperine bites which may manifest as pure haemotoxicity and haemotoxicity with 
acute kidney injury with or without neurotoxicity. 
Due to the ongoing debate between VICC being a consumptive coagulopathy distinct 
from DIC and also the differences in the VICC seen following envenomation by Saw 
scaled viper and Russell’s viper, it is important to describe the clinical and laboratory 
characteristics of VICC according to clinical syndrome that is manifested as well as the 
biting species. This study may therefore provide further details into the pathophysiology 
of VICC in the Indian subset in the two main haemotoxic species. 
SNAKE ANTIVENOM     
Antivenom is considered to be the most important treatment for snake envenoming. 
They are a mixture of polyclonal antibodies to toxins present in snake venoms. They 
are either complete immunoglobulin (IgG) molecules or a fractionated immunoglobulin 
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such as F(ab’)2 or Fab. These are developed in animals, such as horse, sheep, goats and 
rabbits, immunized with repeated small doses of snake venom. The polyclonal nature 
of antivenom is of utmost importance as they results in neutralization of multiple toxins 
present in venom (48).  
There are three major types of snake antivenom used in the world –  
1) Whole IgG 
These antivenom contains intact Immunoglobulin G molecules of approximately 150 
kDa and are purified by ammonium sulphate or caprylic acid precipitation. 
2) F(ab’)2  
F(ab’)2 antivenom is developed after pepsin digestion of whole IgG. 
3) Fab.  
The smallest sized of all anti-venom approximately 50 kDa are produced by papain 
digestion of whole immunoglobulins. 
All these antivenoms have different pharmacodynamic and pharmacokinetic properties, 
and this influences their ability to reach target tissues and duration of action. The degree 
and types of adverse effects also varies among them.  
The World Health Organization recommends that antivenom manufacturing includes 
an assessment of the neutralization of myotoxic, coagulopathic, haemorrhagic, 
necrotizing, oedema forming and the defibrillating effects of venom by the antivenom 
(48). 
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The timing of the onset of toxin effects varies. Some toxins possess rapid onset of 
symptoms within minutes. Pro-coagulant and anticoagulant toxins react within minutes 
with the clotting factors. Therefore, the coagulopathic symptoms begin immediately 
and the reversal of coagulopathy is less observed after giving anti-venom.  
The haemorrhagic toxins also initiate their toxic effect immediately, as the target site is 
in the close proximity of toxins. Immediate administration of antivenom may therefore 
revert central toxic effects.  
Following envenomation which contains neurotoxins leading to a pre-synaptic 
neurotoxicity administration of antivenom should be done before the patient develops 
symptoms.  
Lack of standard predictors and standardized biological markers for early detection of 
on is not practical, as no rapid venom detection facilities are available in the world. 
A venomous snake bite requires urgent medical attention due to the nature of the acute 
insult to the body. Most haemotoxic envenomations have coagulopathy of varying 
severity and require ASV administration to mediate and neutralize the effects of the 
toxin. However, ASV is expensive, and has potential adverse effects. An important 
bedside test that guides the decision to administer ASV is the whole blood clotting time 
(WBCT20) which indicates the extent of coagulopathy (49). 
WBCT20 was initially advocated  as supportive evidence for coagulopathy; however, 
it is now commonly used as a bedside diagnostic test (50). 
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WBCT20 is performed by leaving 5mL of the patient’s blood sample undisturbed in a 
glass tube and assessment of clot formation at the end of 20 minutes. Failure of clot 
formation results in a positive test. The methodology has remained unchanged since the 
time of its inception in 1913 by Lee and White. 
There are limited number of studies on the standardization and validation of this test. 
There are inadequate clinical studies on the effects of physical factors such as length, 
material, temperature of the tube and biological factors such as the type of snake. 
WBCT20 is a useful bedside test especially in resource poor settings where lab-based 
coagulation studies are not easily available. Although it is undoubtedly an invaluable 
bedside test, the reliability of the test has often been questioned (51). 
Due to the lack of standardization and validity of the WBCT20, there is a need for a 
standardized and universally agreed bedside test. WBCT does not necessarily correlate 
with the clinical severity for envenomation, thereby not delivering the essential purpose 
of an early diagnosis of severe VICC, which can lead on to the necessary interventions. 
(49) 
A study done in 2013 on 140 individuals with Russell’s viper envenomation showed 
poor sensitivity of WBCT20 in detecting VICC which led to a delay in administering 
ASV (52).  The authors therefore favoured a more clinical approach to guide treatment 
than WBCT20. A recent publication assessed the performance of WBCT20 in 
comparison to PT/INR in detection of VICC. Out of 987 patients with snake bite, 79 
patients fulfilled criteria for VICC with an INR>1.4 with or without clinical bleeding. 
The WBCT20 was positive in 65/79 patients with a sensitivity of 82% and specificity 
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of 98%. (51) WBCT20 therefore shows poor sensitivity of about 80% across various 
studies and this might delay ASV administration due to false negative WBCT20. Hence, 
studies on standardizing WBCT20 are necessary for clinicians to be able to rely on this 
test. In situations where reliable coagulation studies are not available, there is therefore 
a requirement to devise a reliable, easy-to-do and cost-effective bedside test. 
The properties of clotting are determined by the nature of the surface and area of contact 
of the blood sample as well as the inherent qualities of the sample. These features have 
been utilized in designing activated clotting time tests (ACT). Several techniques have 
been used for the same. Kaolin, Celite and glass are some of the mediators that have 
been used for ACT. Activation means contact of blood with enhancing factors that result 
in more rapid coagulation of the sample. However, on a particular device with 
standardized external factors, these values are reproducible (53). 
The predominant factor determining the duration of ACT is anti-Factor II activity. 
Kaolin provides an internal activating surface, hence making the test independent of the 
size, nature of the material and volumes of the reagents used. Studies on Kaolin based 
ACT have been done in cardiological and neuro-interventional settings (54,55). 
PRINCIPLE: The ACT is a test of whole blood coagulation that gives a single 
parameter for interpretation. Variables  like temperature,  platelets, aprotinin, GP 
IIb/IIIa antagonists, haemodilution and various coagulopathies can alter the result (56). 
ACTs are indicative of inhibition of contact and common pathway (X–Xa) activation 
(57). The ACT tube has an activator substance that will activate factor XII through 
contact activation. The main activator substances used are celite (diatomaceous earth), 
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kaolin, or glass beads, which all have large surface areas for contact. The principle of 
the test is to completely activate the intrinsic coagulation cascade and measure the time 
it takes for generation of a fibrin clot. The sample is heated to 37°C by the machine. 
Depending on the type of machine used, movement is created either through rotation of 
the sample tube, a plunger or through pressure. As a clot forms it imparts resistance 
onto a plunger, a free rolling bar in the sample tube or impedes flow of the blood. The 
end result is the time taken for the sample to form a clot. This is detected photo-optically 
or electromagnetically. The standard tests of coagulation (prothrombin time, activated 
partial thromboplastin time, thrombin time (TT), and fibrinogen level) are plasma tests 
and they measure plasma haemostasis. The ACT measurement uses whole blood and 
incorporates the importance of platelets and phospholipids in coagulation. 
Kaolin based ACT are used in theatres to assess coagulation status in patients on 
continuous anticoagulant infusion following cardiopulmonary bypass, endovascular 
interventions and neurosurgical procedures. Differences between venous and arterial 
blood samples are not known. These values are measured in pre-calibrated machines, 
which lack standard reference values and validation. ACT values vary significantly 
across different devices; hence values must be interpreted in a device-specific manner.  
A modified version of the ACT has been designed in our laboratory that can be easily 
performed on whole blood, at the bedside and takes less time and utilizes commonly 
available low-cost reagents. This test has been named VEMAC TIME- VELLORE  
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MANUALLY ACTIVATED CLOTTING TIME  
Principle of Vemac Time  
    The time it takes for whole blood drawn from a vein and placed in a container invitro 
to clot after the addition of activator. This test measures all the stages of intrinsic 
coagulation. 
Equipment 
Syringe & Needle. 
12 x 100mm glass tube. 
20 ul Sahli’s pipette. 
Stopwatch. 
10-100ul Automated pipette & Tips 
Reagents 
Kaolin (80 mg/ mL) 
Whole blood. 
Normal saline 
Procedure: 
1. Make a clean venipuncture. 
2. Collect 1.5 to 2mL of blood in a syringe. 
3. Start the stopwatch as soon as the blood enters the syringe. 
4. Add 0.5mL of blood into each of two 12x100 glass tubes. 
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5. Add 60uL of kaolin (80mg/ml) to both the tubes, and place the tubes in the stand so 
that they remain upright and undisturbed for 2 minutes. 
6. After 30sec. of incubation take the first tube and gently tip it and look for clot. 
7. When the first tube is clotted record the time and start tipping the second tube every 
30 seconds until it too is found to be clotted. Record the time. 
Results/Interpretation 
The time recorded for the clotting time of the second tube is taken as the clotting time 
(least disturbed). 
Reference range: This was established based on Clinical and Laboratory Standards 
Institute (CLSI) guidelines by performing the test on 120 normal controls in CMC 
Hospital. The reference range was 150-240secs (197.28±28.66secs). 
Advantages of Vemac Time over ACT 
The advantages of the Vemac Time is that it does not require a specialised equipment 
to perform the test. It also does not require a specified temperature to be maintained. It 
can be done at the bedside in any healthcare facility. 
Advantages of Vemac Time over WBCT 20 
The duration of the test is reduced from 20 minutes to less than 5 minutes. The test 
can be performed without any specialised equipment in any healthcare facility which 
has a provision to collect a venous blood sample.   
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RETROSPECTIVE DATA 
1. DEMOGRAPHIC DETAILS 
1.1 GENDER 
A total of 280 patients from the year 2012-2017 who met the inclusion criteria of the 
study were evaluated. 71.07% were males (n=199) and 28.93% (n=81) were females 
with a male: female ratio of 2.45:1.  
 
Figure 1: Gender wise distribution of the study population 
1.2 AGE DISTRIBUTION 
The mean age was 42.2±14.5 years. The mean age among males was 43.02±14.99 and 
in females was 40.16±13.  
 
Figure 2: Age distribution of the study population 
28.93%
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Figure 3: Distribution of patients in each decade (percentage) 
 
1.3 AREAWISE DISTRIBUTION 
The maximum number of patients who presented to our hospital were from Vellore 
43.57% (n=122). 
 
Figure 4: Area wise distribution of the study population 
(Others include Cudappah, Kolar, Kanchipuram and Warangal) 
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Figure 5: Taluk wise distribution of the study population in Vellore district 
 
1.4 SEASONAL VARIATION 
Two peaks were observed in the number of patients being admitted per month with a 
history of snake bite. The first one was in March and the second peak was seen during 
August.  
 
 
Figure 6: Monthly distribution of patients with haemotoxic snake bite 
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2. ENVENOMATION DETAILS 
2.1 TIME OF BITE 
The time of bite was registered for 238 cases. More than a third of the bites (n=88) were 
between 6 pm and midnight.  
 
Figure 7:   Population distribution according to time of bite 
 
2.2 SITE OF BITE 
Majority of bites were in the lower limbs 84.5% (n=223), followed by upper limbs with 
13.3% (n=35).  
 
Figure 8: Distribution according to site of bite 
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3. PATTERN OF VARIOUS CLINICAL MANIFESTATIONS IN THE 
POPULATION 
3.1 LOCAL MANIFESTATIONS 
Local symptoms in the form of any of the following: local swelling in the absence of a 
tourniquet or cellulitis of the affected limb or enlarged tender lymph node draining the 
bitten limb or necrosis, blistering, gangrene or compartment syndrome –absent pulses 
were seen in 100% of the study population. 
 
3.2 NEUROLOGICAL MANIFESTATIONS 
Neurological manifestations included ptosis or ophthalmoplegia, bulbar weakness – 
dysphagia, difficulty in speaking, limb muscle weakness, neck holding time <5s, 
respiratory paralysis-reduced single breath count<10, paradoxical breathing, respiratory 
failure, need for mechanical ventilation. Neurotoxicity in any of these forms were seen 
in 60.7% (n=170) 
 
Figure 9: Distribution according to neurological manifestations 
Patients with neurological manifestations who required ventilatory support formed 
about 20% of the study group.  
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3.3 PTOSIS 
The initial involvement of levator palpebrae superioris in form of ptosis was seen in 
53.9% (n=151) patients.  
 
Figure 10: Distribution according to presence or absence of ptosis 
3.4 RENAL INVOLVEMENT 
Acute kidney injury defined by abrupt (within 48 hours), absolute increase in the 
serum creatinine concentration of ≥0.3 mg/dL (26.4 micromol/L) from baseline; a 
percentage increase in the serum creatinine concentration of ≥50 percent; or oliguria 
of <0.5 mL/kg per hour for more than six hours was seen in 22.5% (n=63) patients.   
 
Figure 11: Distribution according to renal involvement 
Out of the patients with AKI those who required haemodialysis were 49.2% (n=31).  
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4. ENVENOMATION SYNDROMES 
The envenomation syndromes were grouped as PURE HAEMOTOXICITY 
SYNDROME and HAEMOTOXICITY WITH RENAL/NEUROTOXIC 
FEATURES. Pure haemotoxicity were seen in 32.9% (n=92) patients. Combinations 
of haemotoxicity with renal and/or neurological manifestations were seen in 67.1% 
(n=188). 
 
Figure 12: Distribution of envenomation syndromes in study population 
Haemotoxicity was considered when any of the following were present: WBCT20 was 
prolonged, INR above reference interval ≥1.2 bleeding manifestations or 
thrombocytopenia (platelet count <1,00,000/ mm3).  
5. LABORATORY PARAMETERS  
AT BASELINE 
5.1 WHOLE BLOOD CLOTTING TIME 20 
Whole blood clotting time (WBCT 20) more than 20 minutes was considered 
abnormal. 96.4% (n= 270) of the study population showed an abnormal WBCT at 
presentation.  
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Figure 13:  Whole blood clotting time (WBCT 20) at admission 
 
5.2 HAEMOGLOBIN 
Haemoglobin at baseline was done for 277 patients. The mean haemoglobin at 
presentation was 13.9±2.42g% 
 
5.3 PLATELET COUNT 
Platelet count at presentation was done for 273 patients and the median platelet count 
was 1,78,000/cumm.  
 
 
Figure 14: Distribution according to platelet count at admission 
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5.4 INTERNATIONAL NORMALISED RATIO 
 International Normalised Ratio was divided into two groups. INR was considered to 
be abnormal if it was more than or equal to 1.2. At admission INR was done for 267 
patients. An abnormal INR (≥1.2) was seen in 94.38% (n=252). Mean INR at 
presentation was 4.66±3.63 
 
Figure 15: INR at admission 
 13 patients did not have a baseline INR as the samples were either lysed or 
clotted. 
 Among the 267 patients with a documented baseline INR, the WBCT was 
prolonged in 257 (96.25%) patients and normal in 10 patients.  
 Out of the 257 patients with abnormal WBCT at admission 94.55% (n=243) had 
a coexisting abnormal INR of more than 1.2. 
 WBCT was normal in 10 patients among whom 9 had an abnormal INR. 
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5.5 PATTERN OF INR CHANGE OVER 24 HOURS 
The PT with INR was monitored only on patients with evidence of prolonged bleeding 
parameters. Hence the numbers of results available for analysis shows a decreasing 
trend.  
 
Figure 16: Change of INR over 24 hours 
 
 
 
6. ANTI SNAKE VENOM 
Anti-snake venom was administered to all the 280 patients. The mean dose of ASV 
received per patient was 17.43±8.4.  
Reactions to ASV varied from angioedema, itching, urticaria, bronchospasm to 
anaphylactic shock and it was seen in 13.6% (n=38). 
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7. TRANSFUSION REQUIREMENTS 
Blood or plasma products transfusion in addition to ASV were required for 16.8% 
(n=47) patients.   
 
Figure 17: Distribution according to transfusion requirement 
 
 
Figure 18: Distribution of Blood products requirement in patients 
Fresh frozen plasma was required the maximum for 65.9% (n=31) patients.  
7.1 COMPONENT WISE TRANSFUSION 
FRESH FROZEN PLASMA 
Out of the 31 patients who had received FFP transfusion, 29 (%) had an INR more than 
1.5 with bleeding manifestations before the transfusion. The remaining two with an INR 
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less than 1.5 received FFP for haemodialysis procedure and had bleeding 
manifestations.   
194 patients with initial INR more than 1.5 did not receive FFP transfusion since they 
either normalised with ASV or did not have any bleeding manifestation. 
CRYOPRECIPITATE 
15 patients who received cryoprecipitate had a low fibrinogen with associated bleeding 
manifestations. Patients who had a low fibrinogen without any bleeding manifestations 
were not transfused.  
PLATELET RICH CONCENTRATE 
14 patients who received PRC transfusion had severe thrombocytopenia with associated 
bleeding manifestations.  
Patients who had thrombocytopenia without bleeding manifestations were not 
transfused.  
 
8. OUTCOME 
 
Figure 19: Distribution of patients according to the outcome 
Most of the patients were alive at discharge, with 2.5% mortality. 
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PROSPECTIVE GROUP 
9. DEMOGRAPHIC DETAILS OF PATIENTS BETWEEN 2017 AND 2018 
9.1 GENDER 
Among the patients admitted with haemotoxic snake bite in 2017 -2018 there was a 
male preponderance of 83.8%. The male:female ratio was 5.17:1 
 
Figure 20: Gender wise distribution of the study population 
9.2 AGE DISTRIBUTION 
The mean age of this group was 38.11±13.08. The mean age among males was 
37.54±13.48 and among females was 41±11.4 
 
Figure 21: Age wise distribution of the study population 
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9.3 AREAWISE DISTRIBUTION 
The maximum number of patients were from Vellore 57% (n=21).  
 
Figure 22: Area wise distribution of the study population 
(Others include Cudappah and Villupuram) 
 
 
Figure 23: Taluk wise distribution of the study population in Vellore 
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9.4 SEASONAL VARIATION 
The maximum number of patients were seen during the month of July.  
 
Figure 24: Monthly distribution of the study population  
10 ENVENOMATION DETAILS 
10.1 TIME OF BITE 
The time of snake bite was found to be maximum between 6pm to midnight and 37.8% 
of the bites happened during this time.  
 
Figure 25:   Distribution according to time of bite 
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10.2 SITE OF BITE 
Lower limbs were the most common site of bite with 75.6% of patients being bitten in 
the lower limbs. This was followed by upper limbs with 21.6% bites. One patient also 
presented with a bite in the neck region.  
 
Figure 26: Distribution according to site of bite 
 
TIME TO FIRST SYMPTOMS  
The mean time taken for the first symptoms to start after snake bite was 55.19 
minutes. It ranged from 5 minutes to 6 hours.  
TIME TO RECEIVE FIRST AID 
The median time to receive first aid was one hour. All patients received first aid 
within 12 hours.  
TIME TO RECEIVE FIRST ASV 
The mean time taken to receive the first dose of ASV was 3.36 hours. It ranged from 
30 minutes to 19 hours.  
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The median time to the first bleeding symptoms was 60 minutes. It ranged from 5 
minutes to 12 hours. 
TIME TO FIRST SYSTEMIC BLEEDING  
Systemic bleeding in the form of oral cavity bleed, haematuria, hematemesis, 
haematochezia and malena was present in 54.1% of patients. The mean time to the first 
systemic bleed was 5.65 hours. It ranged from 1 hour to 24 hours.  
 
11. PATTERN OF VARIOUS CLINICAL MANIFESTATIONS IN THE 
POPULATION 
 
11.1 LOCAL MANIFESTATIONS 
Local symptoms in the form of any of the following: local swelling in the absence of a 
tourniquet or cellulitis of the affected limb or enlarged tender lymph node draining the 
bitten limb or necrosis, blistering, gangrene or compartment syndrome –absent pulses 
were seen in 100% of the study population. 
 
11.2 NEUROLOGICAL MANIFESTATIONS 
Neurological manifestations included ptosis or ophthalmoplegia, bulbar weakness – 
dysphagia, difficulty in speaking, limb muscle weakness, neck holding time <5s, 
respiratory paralysis-Reduced single breath count<10, paradoxical breathing, 
respiratory failure, need for mechanical ventilation. Neurotoxicity in any of these forms 
were seen in 51.4% (n=19) 
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Figure 27: Distribution according to neurological manifestations 
 
Patients with neurological manifestations who required ventilatory support were 8.1% 
(n=3).  
11.3 PTOSIS 
The initial involvement of levator palpebrae superioris in form of ptosis was seen in 
48.6% (n=18) patients.  
 
Figure 28: Distribution according to presence or absence of ptosis 
11.4 RENAL INVOLVEMENT 
Acute kidney injury defined by abrupt (within 48 hours), absolute increase in the serum 
creatinine concentration of ≥0.3 mg/dL (26.4 micromol/L) from baseline; a percentage 
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increase in the serum creatinine concentration of ≥50 percent; or oliguria of <0.5 mL/kg 
per hour for more than six hours was seen in 45.9% (n=17) patients.   
 
Figure 29: Distribution according to renal involvement 
Patients with AKI who required haemodialysis were 16.2% (n=6).   
12. ENVENOMATION SYNDROMES 
The envenomation syndromes were grouped as PURE HAEMOTOXICITY 
SYNDROME and HAEMOTOXICITY WITH RENAL/NEUROTOXIC 
FEATURES. Pure haemotoxicity were seen in 24.3% (n=9) patients. Combinations of 
haemotoxicity with renal and/or neurological manifestations were seen in 75.7% 
(n=28). 
 
Figure 30: Distribution of envenomation syndromes in study population 
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Haemotoxicity was considered when any of the following were present: WBCT20 was 
prolonged, INR above reference interval ≥1.2), bleeding manifestations or 
thrombocytopenia (platelet count <1,00,000/ mm3).  
13. LABORATORY PARAMETERS  
AT BASELINE 
13.1 WBCT 
The Whole blood clotting time at presentation was more than 20 minutes in 81.1% 
(n=30).  
 
Figure 31: Distribution according to whole blood clotting time at presentation 
 
13.2 HAEMOGLOBIN 
Haemoglobin at baseline was done for 37 patients. The mean haemoglobin at 
presentation was 13.78±2.46g% 
 
13.3 PLATELET COUNT 
The platelet count at admission was done for all 37 patients. 5.4% (n=2) had severe 
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(platelet count between 50,000/cumm and 1,00,000/cumm) was seen in 5.4% (n=2) 
patients. Mild thrombocytopenia (platelet count between 1,00,000/cumm and 
1,50,000/cumm) was present in 21.62% (n=8). A normal platelet count of more than 
1,50,000/cumm was seen in 67.56% (n=25) patients.  
 
Figure 32: Distribution according to platelet count at admission 
 
13.4 INTERNATIONAL NORMALISED RATIO 
The international normalised ratio was abnormal (≥1.2) in 89.18% (n=33) patients.  
 
Figure 33: Distribution according to INR at admission 
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13.5 FIBRINOGEN 
Fibrinogen at admission was abnormal (<150) for 56.75% (n=21) patients.  
 
 
Figure 34: Distribution according to Fibrinogen at admission 
 
14. ANTI SNAKE VENOM 
Anti-snake venom was administered to all the 37 patients. The mean dose of ASV 
received from other hospital prior to reaching our centre was 8±6.9. The mean dose of 
ASV at our centre was 10.57±5.11 
18.91%(n=7) had a reaction to ASV. Reactions varied from angioedema, itching, 
urticaria, bronchospasm to anaphylactic shock. 
 
 
 
 
 
 
56.75
43.24
0
10
20
30
40
50
60
Less than 150
More than 150
 65 
 
Characterisation of Venom Induced Consumption Coagulopathy (VICC) in patients with Haemotoxic Snake 
Bite and the effects of Blood Products on Coagulation Parameters. 
 
15. VARIATION OF LABORATORY PARAMETERS OVER 24 HOURS 
15.1 PLATELET VARIATION OVER 24 HOURS 
The platelet count at admission varied from 35,000/cumm to 3,08,000/cumm.  
 
Figure 35: Variation of platelet count over 24 hours 
15.2 INR VARIATION OVER 24 HOURS 
The INR at presentation varied from 1.12 to 10. It ranged from 3.05 to 0.77 at 6 hours.  
At 12 hours it ranged from 2.84 to 0.83. By 24 hours the range was 1.65 to 0.84  
 
 
Figure 36: Variation of INR over 24 hours 
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15.3 FIBRINOGEN VARIATION OVER 24 HOURS  
Fibrinogen at presentation ranged between a not detectable value to 455mg/dL.  Those 
who had abnormal values were tested again at 6hours, 12hours or 24hours till they 
normalised.  
 
Figure 37: Variation of fibrinogen over 24 hours 
16. TIME TO NORMALIZATION OF COAGULATION PARAMETERS 
TIME TO NORMALISATION  
The mean platelet counts for the pure haemotoxic group and the haemotoxicity 
+renal/neurotoxicity group have been plotted against time to show the pattern of 
normalisation. The pure haemotoxic group did not have thrombocytopenia at admission. 
Whereas the mean time to normalisation in the group with haemotoxicity 
+renal/neurotoxicity was 17.3±7.94 hours  
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Figure 38: Time to normalization for Platelet count (Mean values) 
The mean values of INR for the pure haemotoxic group and the haemotoxicity 
+renal/neurotoxicity group have been plotted against time to show their pattern of 
normalisation. The mean time to normalisation of INR in the pure haemotoxic group 
was 14±6 hours. The mean time to normalisation among the haemotoxicity 
+renal/neurotoxicity group was 10.75±6.61 hours.  
 
Figure 39: Time to normalization for INR (Mean values) 
 
The mean values of fibrinogen for the pure haemotoxic group and the haemotoxicity 
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haemotoxic group was 11.25±5.9 hours. The mean time to normalisation among the 
haemotoxicity +renal/neurotoxicity group was 6.5±1.7 hours. 
 
Figure 40: Time to normalization for Fibrinogen (Mean values) 
 
 
17. TRANSFUSIONS 
In addition to ASV, transfusions were required for 21.6% (n=8) patients. 
 
Figure 41: Distribution of patients requiring transfusion 
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concentrate transfusion was required for 25% (n=2). Cryosupernatant was transfused 
for 25% (n=2) patients. Cryoprecipitate transfusion was needed for 12.5% (n=1) patient.  
 
Figure 42: Distribution according to product transfused 
 
FRESH FROZEN PLASMA  
Out of the 4 patients who had received FFP transfusion, 2 had an INR more than 1.5 
with bleeding manifestations before the transfusion. One patient had received FFPs 
from elsewhere and his INR was normal at presentation to our center. Another patient 
had a prolonged APTT with systemic bleed hence FFP was transfused. 
22 patients with INR more than 1.5 did not receive FFP transfusion since they either 
normalised with ASV or did not have any bleeding manifestation. 
 
CRYOPRECIPITATE 
One patient who received cryoprecipitate had a low fibrinogen with associated bleeding 
manifestations. Patients who had a low fibrinogen without any bleeding manifestations 
were not transfused.  
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PLATELET RICH CONCENTRATE 
Two patients who received PRC transfusion had thrombocytopenia with associated 
bleeding manifestations.  
Patients who had thrombocytopenia without bleeding manifestations were not 
transfused.  
18. OUTCOME 
Out of the 37 patients 91.8% (n=34) were discharged in a stable condition. There was 
no mortality in the patients admitted.  
 
 
 
Figure 43: Distribution of patients 3according to condition at discharge 
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19. COMPARISON BETWEEN TWO GROUPS IS SHOWN BELOW: 
Table 1: Comparison between pure haemotoxic group and haemotoxicity+ 
neurotoxicity/renal involvement 
 PURE HAEMOTOXIC HAEMOTOXICITY+ 
NEUROTOXICITY/RENAL INVOLVEMENT 
TOTAL NUMBER OF 
PATIENTS 
9 28 
MALE: FEMALE 8:1 5:1 
AGE   
TIME TO SYMPTOMS 23.33 minutes 60.10minutes 
TIME FOR FIRST 
BLEEDING 
36.67minutes 133 minutes 
SYSTEMIC BLEED 3 patients 17 patients 
TIME TO SYSTEMIC 
BLEED 
2.67hours 5.75 hours 
VENTILATOR 1 patient 4 patients 
DIALYSIS None 6 patients 
MEAN ASV 15.89 20.29 
LABORATORY 
PARAMETERS 
Baseline 6HRS 12HRS 24HRS BL 6HRS 12HRS 24HRS 
WBCT (prolonged) 8sec    22sec    
INR (mean) 5.21 1.85 1.36 1.06 2.67 1.16 1.1 1.08 
APTT RATIO 2.04 1.06 0.93 0.44 1.41 1.05 0.6 0.2 
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FIBRINOGEN (mg/dl) 81.67 139.88 169.25 242 155.64 185.6 181 245.5 
PLATELET (/cumm) 190888 198888 203571 222000 170000 137250 148181 174250 
TOTAL COUNT (/cumm) 20322    17610    
TRANSFUSION (total) 1 7 
RED CELLS 0 4 
PLATELETS 0 2 
FFP 1 3 
CRYOPRECIPITATE 0 1 
CRYOSUPERNATANT 0 2 
OUTCOME All discharged 25 discharged, 1 discharged with 
sequalae, 2 DAMA 
 
20. VEMAC Time  
Vemac Time standardised in our hospital was compared with PT values in prospective 
group. A PT of more than 13s was considered abnormal.  
Table 2: Vemac Time and PT comparison 
 PT prolonged (> 13 secs) PT not prolonged (<13 secs) 
Vemac Time prolonged 27 0 
Vemac Time normal 6 4 
 
The sensitivity of the test was found to be 81.82% and specificity was 100%.  
Positive predictive value of the test was 100%.  
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When compared to a composite diagnosis of VICC it was found to have positive 
predictive value of 100%.  
Table 3: Vemac Time and VICC comparison 
 VICC NO VICC 
Vemac Time prolonged 27 0 
Vemac Time normal 10 0 
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DISCUSSION: 
In the present study we have attempted to characterize the effects of snake bite on the 
haemostatic system, transfusion requirements and effect of transfusion on haemostatic 
parameters.  
RETROSPECTIVE DATA: 
DEMOGRAPHIC DETAILS 
In the retrospective study group a total of 280 cases of haemotoxic snake bite were 
identified. The victims of snake bite were predominantly male (72.5%, n = 200), and 
the male to female ratio was 3:1. Males are affected more often than females, as they 
constitute the working majority who are actively engaged in farming and other outdoor 
activities. Our findings concur with those of earlier study by Mondal et al where they 
revealed that majority of the patients were males (79.8%) from rural areas (85.1%). A 
study conducted in viper bites in a tertiary centre in South India showed a male female 
ratio of 1.4:1. A similar study from another southern state showed a male preponderance 
(58%) (58).  
The mean age of retrospective group was 42.2 ± 14.5 years (range16-75 years).  The 
mean age of the male patients was 43 (range 19-65) years, and that of female patients 
was 40.1 (range 25-65) years. Decade -wise distribution of male and female snake bite 
cases by Monteiro et.al showed that majority of snake bite victims were aged 25-55 
years (n =25, 80.6%), with the peak incidence in the 3rd and 5th decades of life. In our 
study retrospective data showed almost similar distribution among second to fifth 
decade of life. 
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Seasonal variation in the incidence of snake bite was observed in our study with 
maximum number of bites occurring during August (15.3 %). Such variation was also 
observed in study conducted by Nagnath R et al among Maharashtra victims with 
maximum number of bites occurring in rainy season (83.3%) between June to October 
and highest number of cases during August (28.1%). Hansdak et al also reported that 
51% of cases occurred during monsoon (August–October). Similar studies have shown 
most bites observed during the months of May to November which represents the 
monsoon. This poses increased risk to farmers as they harvest their crops during these 
seasons. Studies conducted at other centres also noticed a similar increase in the 
incidence of snake bites during the monsoon when compared to the drier summer. Study 
conducted by Monteiro et al showed the peak incidence in snake bite cases during 
October, followed by September (59). 
 
ENVENOMATION DETAILS 
Snake bites are more common on the lower extremities due to accidental stampede 
while walking or playing. In a study conducted by Kshirsagar VY et al among rural 
population they found that 120 (74.04%) patients had bite marks on the lower limbs 
similar to various studies which have shown that in 70-86% patients bite marks are 
present on the lower limbs (60). Most of the victims in our study were bitten mostly in 
the fields during 6pm to midnight (n = 88, 37%) and on their lower limbs (n = 223, 
84.5%).  
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In a study on snake bite envenoming from Kerala, 200 cases were analysed which 
showed 93% were outdoor bites with 81% of bites in the lower limbs (58).  
Characteristics of the 143 victims of snake bites from South-eastern Nepal showed 
agriculture was the dominant profession (44%) and 49% of the victims lived in a 
traditional hut with mud walls. Most of the snake bites occurred during the rainy season 
(68%), outside the house (82%), while farming (21%), doing other work (32%), or 
walking (32%) and mostly during the day (50%) or between 6:00 PM and midnight 
(40%) (61). 
In a study from Maharashtra out of 38 cases of Russell's viper bites studied in one year, 
28 (73%) were males. 29(76%) of these cases had bites to their lower extremities(62). 
 Russell’s viper is very aggressive snake. Its fangs are long and sharp. It is diurnal in 
habit. It bites a person working in a farm, handling the debris or harvesting or walking 
bare foot in tall grass. 
PATTERNS OF CLINICAL MANIFESTATIONS 
The categorisation of syndromes was based on the WHO South East Asia Guidelines 
(2016). Russell’s viper bite syndromes include haemotoxicity or haemotoxicity in 
combination with neurotoxicity and/or acute kidney injury. Pure haemotoxicity could 
either be due to Saw Scaled viper bites or Russell’s viper. Krait bite syndrome causes 
neuroparalysis without local swelling and may have associated abdominal pain. Cobra 
bite syndrome causes neuroparalysis with local swelling. The main aim of our study 
was to look at the coagulation parameter abnormalities and the transfusion requirements 
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for patients with snake bites. Hence, we analysed only patients presenting with 
haemotoxic manifestations.  
All the 280 patients brought to hospital had local swelling and pain at the site of bite, 
associated with bleeding from the site. Local signs of envenomation and systemic 
haemotoxic manifestations of envenomation were present in all cases. Haemotoxicity 
was considered when any of the following were present: WBCT20 was prolonged, INR 
above reference interval (>1.5), bleeding manifestations or thrombocytopenia (platelet 
count <1,00,000/ mm3).  Study conducted from Southern India showed 40% of the 
victims had bleeding from the site of bite. This finding is similar to studies by Bhat RN 
and Reid et al. Other manifestations from the same study included generalized 
ecchymosis, purpura or hematomas, frank or microscopic haematuria, haemoptysis, 
gingival bleeding, hematemesis (63). 
 Study conducted from our centre which included 167 patients with systemic 
envenomation showed 102 patients with combinations of haemotoxicity with 
neurotoxicity and/or acute kidney injury (61%) (which were probably due to Russell's 
viper envenomation). The most common Russell's viper syndromes were haemotoxicity 
with neurotoxicity and haemotoxicity with neurotoxicity and acute kidney injury. There 
were 12 cases (7.2%) with neurotoxicity without local swelling (probable Krait bite) 
and 18 cases (10.8%) with neurotoxicity with local swelling (probable cobra bite). All 
the deaths occurred in the syndromes of Russell’s viper with haemotoxicity with AKI.  
Our present study showed associated neurotoxicity in 60.7% patients and 20.6% of them 
required ventilatory support. Ptosis was seen in 53.9% of patients. Associated renal 
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involvement was seen in 22.5% of patients. All symptoms including haemotoxicity, 
local manifestations, neurotoxicity, ptosis, renal involvement and rhabdomyolysis 
together was present in 8.2% of patients.  
 
Figure 44: Symptoms wise distribution of patients 
 
In another study conducted on 1,500 cases from a tertiary care centre in Malabar, North 
Kerala, India showed hemotoxic bites (61%) exceeded neurotoxic bites (34%) by a 
significant margin. Same study showed, haematuria as the most common (246 patients) 
symptom followed by bleeding gums in 218 patients. Haemoptysis was seen in 172 
patients. Retinal haemorrhages were seen in 106 patients (64).  
In a study of 138 patients from Western India looking into the complications of 
envenomation with snake bite showed haemorrhagic manifestations 123(89%). Other 
presenting manifestation were haematuria 38.4%, renal failure 29.7%, ptosis 7.3%, 
respiratory paralysis 7.3% and intracranial bleeding 2.2% in the same study. However, 
no cardiotoxicity was reported (65). Our study showed 3 cases with cardiac 
manifestations in the form of poor systolic function, suspected Kounis syndrome 
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characterised by acute coronary syndrome or ST-Segment elevation myocardial 
infarction resulting from an allergic reaction, myocarditis and one patient died of sudden 
cardiac death due to probable arrhythmia. Hayat and Khan also reported haemorrhagic 
manifestation in 95% and neurotoxicity in 5% of cases (66). 
LABORATORY PARAMETERS 
Snake venom contains various proteins (like prothrombin activators, thrombin like 
enzymes, phospholipases, factor X activating proteins etc.) which block different levels 
of coagulation or it may cause excessive clot formation leading to consumption 
coagulopathy. In most of the cases PT and APTT both are raised.  
In a study conducted in a tertiary care centre by Dasaraju showed prolonged PT in 66% 
of the patients which was comparable with another study conducted by Monteiro et al, 
Ramamurthy et al, Harshavardhana et al and David et al who found deranged PT in 
32.30%, 40.00%, 56.00% and 47.50% of patients respectively (59,63,67,68). In the 
study by Manisha et al, 75.89% of the patients showed deranged PT, which was similar 
to the Mahmood et al (70.00%) studies (62) .  
In our study PT was not considered as a parameter for analysis due to inherent variance 
relating to thromboplastin in the reagent and method of analysis. Instead, the INR is a 
more standardised parameter which offers practical advantages for monitoring was 
considered. We considered an INR more than or equal to 1.2 as abnormal. At 
presentation the majority of our patients, 94.38% of patients had an abnormal INR.  
In a cohort study of patients with confirmed or suspected snake bite recruited to the 
Australian Snake bite Project (ASP) from January 2002 to April 2009 showed that in 
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178 of the 206 patients (86%), the INR was abnormal (> 1.2) on the first set of tests. In 
the same study by Graham et al suggests that the combination of tests for INR, APTT 
and CK level and serial neurological examinations is able to reliably detect envenomed 
patients within 12 hours (69). If there is no progression of symptoms or evidence of 
coagulopathy the patient can be discharged after rechecking laboratory parameters that 
INR is not elevated. Elevated INR indicates envenomation or impending coagulopathy.  
In our study out of 273 patients for whom platelet count was done, 37.64% had 
thrombocytopenia at presentation. Baseline fibrinogen was available for 23 patients, 
among whom 6 had an undetectable fibrinogen. A study conducted by Moriarity et al 
looking into the role of coagulation markers in snake envenomation showed coagulation 
marker abnormalities in 35 (26.7%) of the 131 snake bite patients (70). Seventeen 
(13.8%) had an abnormal PT, 17 (13.9%) had an abnormal APTT 8 (6.2%) had 
thrombocytopenia, and 5 (13.2%) had abnormal fibrinogen concentrations (70).  
In our study, deranged APTT ratio was seen in 39.8% of patients. Mahmood et al had 
similar results with 71.30% of patients having deranged APTT (59). Monteiro et al, 
Ramamurthy et al, Harshavardhana et al and David et al found deranged APTT in 
29.00%, 40.00%, 62.00% and 32.50% of patients respectively (59,63,67). 
ANTI SNAKE VENOM 
In a study by Monteiro et al around 4-32 ASV vials were administered to each patient, 
at an average of 11.1 ASV vials per patient (59). In our study the mean dose of ASV per 
patient was 17.43±8.4. 
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In a previous study conducted in our institute the hypersensitivity reaction rate to ASV 
was about 8% (67). In our study it was found to be 13.6%.  
TRANSFUSION 
Blood products have been administered alone and in addition to antivenin in patients 
with snake bite-induced coagulopathies. Envenomed patients remain at risk of major 
haemorrhagic complications such as intracranial haemorrhage for a significant time 
period after antivenom treatment. This has prompted the use of blood products as 
replacement for clotting factors. However, there is a concern that the provision of 
clotting factors will worsen the coagulopathy, as more substrate will be available for 
the procoagulant toxins present in the venom to activate. Furthermore, there are also 
risks associated with the use of blood products like haemolytic reactions, nonhemolytic 
reactions, and infectious complications. 
A recent randomized controlled trial in Australia of FFP in VICC showed that FFP (10-
15 mL/kg up to maximum of 4 units, about 1000 mL) given within 4 hours of antivenom 
administration resulted in a more rapid recovery in the PT/INR (71). In our study 16.8% 
of patients required either blood and/or plasma products transfusion in addition to ASV. 
All the patients who received plasma products transfusion had bleeding manifestations. 
In a study from another tertiary care centre 20.3% of the snake bite victims were 
transfused with blood products (72).  
The main component transfused was FFP (65.9%) followed by Red cells (53.2%), 
cryoprecipitate (31.9%), platelet concentrates (29.8%) and cryosupernatant (10.6%). 
The mean dosage of FFP was 5±2.6 units and highest number of FFP required by any 
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patient was thirteen. The lab parameters which were usually ordered to substantiate the 
use of FFP were 20min WBCT, PT & INR, APTT & Fibrinogen.  
Other indications for transfusion were surgical interventions like fasciotomy, 
debridement or haemodialysis, in the absence of overt bleeding. 
Out of the 2.5% (n=7) who had expired, 2 patients had not received any transfusions. 
The remaining 1.78% (n= 5) patients had been transfused blood and/or plasma products. 
Four patients had received FFP and cryoprecipitate. Three of these patients had received 
platelets also.  
PROSPECTIVE STUDY GROUP 
In the prospective study group a total of 37 cases of haemotoxic snake bite were 
identified from 2017-2018. The victims of snake bite were predominantly male (83.8%, 
n = 31), and the male to female ratio was 5:1. In a study by Alirol et al. about snake bite 
in Southeast Asia, it was concluded that there was a significant 2:1 male predominance 
over female among victims and that lower extremities were the most prevalent sites of 
snake bites (10). In our study 75.67% of the patients had snake bites in the lower limbs. 
Maximum bites were seen in between 6pm and midnight (37.8%) which was similar to 
our findings in the retrospective study group.  
In our prospective group study, the median time to receive first aid was one hour, with 
the maximum time being 12 hours. All patients received first aid within 12 hours. The 
previous study from our institute has shown about three fourth of the patients sought 
first aid in local clinics and peripheral hospitals prior to definitive treatment in the 
tertiary hospital (67). Most of the cases were admitted within 24 h of the bite. This 
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reflects an increasing awareness about the need for hospital-based care for snake bites 
and a possible change in attitude of patients. In a study conducted by Eslamian et al 
mean time between snake bite occurrence and reaching first medical centre was about 
six hours (73).  
In a study by Padhiyar et al 62.5% (40/64) patients had received ASV before they were 
referred to tertiary care centre, 51.6% (33/64) had received Injection Tetanus Toxoid, 
and 45.3% (29/64) had a tourniquet tied at or above the site of bite (72). In our study 
83.78%(n=31) patients had received ASV prior to reaching our centre, reflecting the 
better availability of ASV in smaller healthcare facilities as a result of sustained 
advocacy.  
The mean time taken for the first symptoms to start after snake bite was 55.19 minutes. 
It ranged from 5 minutes to 6 hours. Since envenomation is a function of several 
variables including dose of venom (in the snake bite), body mass of the patient and 
location of bite, our small sample size precludes us from making any significant 
conclusions on this parameter. 
The median time to receive first aid was one hour. All patients received first aid within 
12 hours. The mean time taken to receive the first dose of ASV was 3.36 hours. It ranged 
from 30 minutes to 19 hours. The median time to the first bleeding symptoms was 60 
minutes. It ranged from 5 minutes to 12 hours. Systemic bleeding in the form of oral 
cavity bleed, haematuria, hematemesis, haematochezia and malena was present in 
54.1% of patients. The mean time to the first systemic bleed was 5.65 hours. It ranged 
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from 1 hour to 24 hours. This is similar to a study by Kumar et al the mean time to reach 
to hospital was 12.1 ± 21.4 hours (range 1-120 hours (64).  
Out of the 37 patients, 89.18% (n= 33) had an abnormal INR at presentation. Out of this 
39.39%(n=13) patients normalised by 6 hours. Out of the remaining 20 patients, 14 
normalised by 12 hours and five patients normalised by 24 hours. Two of the patients 
who did not normalise by 12 hours received FFP. One of these patients showed 
nephrotoxicity and underwent haemodialysis. 
Out of the 9 patients who displayed features of isolated haemotoxicity syndrome, all 
had abnormal INR. These patients took a median time of 12 hours for normalisation 
with a maximum of 24hours. Fibrinogen was abnormal in 7 of these patients which 
normalised within a median time of 9 hours. Fresh frozen plasma transfusion was 
required for one patient who had a baseline INR of 3.29 and normalised only by 12 
hours. The dose of FFP in our study was 10–15 mL kg–1. 
Out of the 28 patients with haemotoxicity and neurotoxicity/renal involvement, 25 had 
an abnormal INR at presentation. These patients normalised with a median time of 6 
hours. However, 7 patients normalised only by 12 hours. Fibrinogen was abnormal for 
32.43% (n=12) patients and the median time for normalisation was 6 hours. Plasma 
products were transfused for 16.2% (n=6) patients in this group. In a study done by 
Dempfle et al he concluded that intra venous administration of anti-snake venom 
resulted in normalized coagulation parameters within 48 hrs whereas in the study by 
Agarwal et al they saw that 51 out of 53 cases showed normalization of coagulation 
markers 12 hrs after administration of anti-snake venom (74). In our study it was 
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difficult to ascertain time to normalization from time of administration since most of 
the patients received ASV prior to admission at our hospital. 
A complete comparative analysis of two envenomation syndromes is shown in table. 
Study by Isbister et al on a multicentre open-label randomized controlled trial in 
Australia to show utility of fresh frozen plasma for treating Venom-Induced 
Consumption Coagulopathy, showed that the administration of FFP within 4 hours of 
antivenom administration results in more rapid restoration of clotting function in the 
majority of patients with VICC (71). Almost three-quarters of patients receiving FFP 
had an INR of < 2 at 6 hours after antivenom administration, and this was also associated 
with more rapid complete recovery to a normal INR. In study by Harshavardhana, et al 
patients with coagulopathy had prolonged hospital stay and required more blood 
products transfusion. In his study he had 13 patients with haemoglobin less than 10 g/dl 
and approximately hospitalized for 22 days and they received 38 packed red cells. 24 
patients had platelets less than 1 lakh and approximately hospitalized for 28 days and 
they received 102 platelet units. INR was more than 1.5 in 24 patients and hospitalized 
for 25 days and they received 136 fresh frozen plasma (63). Whole blood clotting time 
was prolonged more than 20 minutes in 30 patients and approximately hospitalized for 
27 days and they received 488 ASV vials. In our study anti-snake venom was 
administered to all the 37 patients. The mean dose of ASV received from other hospital 
prior to reaching our centre was 8±6.9. The mean dose of ASV at our centre was 
10.57±5.11. 
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The Vemac Time standardised at our centre was compared with WBCT 20 and 
Prothrombin Time to analyse its utility in detecting envenomation by haemotoxic snake 
bite. Using PT as the gold standard we found that Vemac Time had 100% specificity 
with positive predictive value of 100%.  
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LIMITATIONS: 
 A major limitation of the present study is in the retrospective group where a 
retrospective chart review was done and some of the important data may be 
incomplete or insufficient, thus may affect statistical analysis. 
 The selection bias due to a single centre data is justifiable. Referral bias explains 
why all of our patients were envenomated, and might have resulted in the 
transfer of more seriously ill patients to our facility. 
 Many snake bite cases are treated at the primary healthcare centres and not 
referred to higher centres, leading to an underestimation of the morbidity status 
in studies done at tertiary healthcare centres. There may be a similar 
underestimation of snake bite mortality in the study. 
 Vemac Time was performed at the bed side in Accident & Emergency by 
clinician. The precision of the test may be better when performed by laboratory 
staff under controlled conditions.  
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CONCLUSION: 
RETROSPECTIVE DATA 
 There is a relatively higher prevalence of snake bite in males. 
 There is a seasonal variability of the snake bite cases, we found bimodal 
distribution of the cases occur during the month of March and August 
 The majority of bites were between 6 pm - midnight with majority of bites 
in the lower limbs. 
 Local symptoms in any form were seen in 100% of the study population. 
 The envenomation syndromes were grouped as pure haemotoxicity 
syndrome and haemotoxicity with renal/neurotoxic features. Pure 
haemotoxicity were seen in 32.9% patients. 
 At admission INR was abnormal in 94.38% of population. 
 
 All patients received ASV and 13.6% of patients had a reaction to ASV. 
 16.8% patients required either blood or plasma products transfusion in 
addition to ASV.  
 FFP was the most commonly transfused blood product.  
 All patients who required blood transfusion had bleeding manifestations. 
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PROSPECTIVE STUDY: 
 Pure haemotoxicity was seen in 24.3% patients. 
 The International Normalised Ratio was abnormal (≥1.2) in 89.18% 
patients. 
 32.43% of patients had thrombocytopenia at presentation.  
 Fibrinogen at admission was abnormal (<150) for 56.75% (n=21) patients. 
 Venom Induced Consumption Coagulopathy was seen in 100%(n=37) 
patients.  
 In addition to ASV, transfusions were required for 21.6% patients.  
 VICC is a distinct entity that appears to have better prognosis when treated 
aggressively with ASV and blood components. 
 The Vemac Time appears to be a sensitive and highly specific test that can 
be rapidly and reproducibly performed at the bedside for rapid diagnosis 
of envenomation. 
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Figure 45: Indian Cobra (Naja naja) 
 
 
 
 
 
Figure 46: Common krait (Bungarus caeruleus) 
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Figure 47: Russell’s viper (Daboia russelii) 
 
 
 
 
 
Figure 48: Saw-scaled viper (Echis carinatus) 
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1.00
2.00
14.40
9000.
00
16500
0.00
14.30
1.30
29.80
0.96
350.0
0
14.20
18000
0.00
10.20
0.93
31.50
30.90
1.02
0.00
0.00
2.00
31.00
18906
8H
2.00
43292
.00
1.00
1.00
2.00
2.00
2.00
1.00
1.00
28.00
2.00
NA
2.00
20.00
0.00
20.00
1.00
22.00
Russe
ll's vi
per24
0.00
6.00
6.00
1.00
360.0
0
2.00
1.00
2.00
6.00
21500
.00
10100
0.00
12.90
1.18
45.90
1.49
200.0
0
7.60
55000
.00
10.30
0.94
36.20
30.90
1.17
6.50
33000
.00
0.00
6.70
77000
.00
10.30
0.90
0.00
1.00
12.00
3.00
32.00
18940
0H
1.00
43297
.00
1.00
1.00
1.00
1.00
2.00
2.00
2.00
8.00
1.00
Anap
hylax
is
2.00
2.00
12.00
14.00
1.00
2.00
Russe
ll's vi
per12
0.00
3.00
3.00
2.00
2.00
2.00
2.00
16.70
18300
.00
13900
0.00
36.90
3.35
35.50
1.15
35.00
13.70
10500
0.00
9.00
0.83
200.0
0
23.40
30.90
0.76
17500
0.00
0.00
0.00
2.00
33.00
18940
7H
2.00
43297
.00
1.00
1.00
1.00
1.00
2.00
1.00
2.00
11.00
1.00
NA
2.00
20.00
0.00
20.00
1.00
5.00
Russe
ll's vi
per1
0.00
0.50
0.50
2.00
2.00
2.00
2.00
10.40
27100
.00
17800
0.00
16.90
1.55
28.30
0.92
200.0
0
10.20
16300
0.00
11.00
1.01
29.30
30.90
0.95
0.00
0.00
2.00
34.00
02632
5C
1.00
43306
.00
1.00
1.00
2.00
2.00
2.00
1.00
2.00
24.00
1.00
NA
2.00
0.00
10.00
10.00
1.00
12.00
Russe
ll's vi
per36
0.00
12.00
12.00
1.00
360.0
0
1.00
6.00
1.00
1.00
14.40
14800
.00
11500
0.00
18.50
1.69
31.00
1.00
172.0
0
12.60
11800
0.00
10.80
1.00
29.50
30.90
0.95
13.70
13000
0.00
0.00
0.00
2.00
35.00
35016
7H
1.00
43305
.00
1.00
1.00
2.00
2.00
2.00
1.00
1.00
48.00
1.00
NA
2.00
2.00
20.00
22.00
1.00
13.00
Russe
ll's vi
per36
0.00
10.00
12.00
1.00
360.0
0
1.00
10.00
1.00
1.00
13.40
18900
.00
17200
0.00
23.80
2.16
29.70
0.96
32.00
13.40
72000
.00
13.40
1.23
200.0
0
37.50
30.90
1.21
12.20
60000
.00
18.60
1.70
46.00
1.49
9.30
15000
0.00
18.00
1.65
250.0
0
41.60
1.35
1.00
18.00
2.00
36.00
35073
1H
1.00
43311
.00
1.00
1.00
1.00
1.00
2.00
1.00
2.00
10.00
1.00
NA
2.00
10.00
10.00
20.00
1.00
4.00
Russe
ll's vi
per1
0.00
1.00
1.00
1.00
10.00
2.00
1.00
2.00
15.50
12900
.00
13900
0.00
120.0
0
10.00
49.40
1.60
20.00
12.20
95000
.00
12.50
1.13
200.0
0
29.50
30.90
0.95
11.40
92000
.00
9.90
0.91
31.00
1.00
17400
0.00
0.00
2.00
37.00
35163
4H
1.00
43322
.00
1.00
1.00
1.00
1.00
2.00
2.00
2.00
11.00
1.00
NA
2.00
0.00
10.00
10.00
2.00
5.00
Russe
ll's vi
per12
0.00
3.00
5.00
2.00
2.00
2.00
2.00
14.50
7000.
00
25900
0.00
12.60
1.16
25.00
0.81
300.0
0
13.90
23500
0.00
13.80
1.26
24.50
30.90
0.79
0.00
0.00
2.00
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THE END 
